Effects of Psychoactive Chemicals on Commercial Driver Health and Performance: Stimulants, Hypnotics, Nutritional, and Other Supplements (2011)

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

93 Afaghi, A., H. O’Connor, and C.M. Chow, “High-Glycemic- Index Carbohydrate Meals Shorten Sleep Onset,” American Journal of Clinical Nutrition, Vol. 85, 2007, pp. 426–430. Akerstedt, T. and G. Ficca, “Alertness-Enhancing Drugs as a Countermeasure to Fatigue in Irregular Work Hours,” Chronobiology International, Vol. 14, No. 2, 1997, pp. 145–158. Alford, C., H. Cox, and R. Wescott, The Effects of Red Bull Energy Drink on Human Performance and Mood, Amino Acids, Vol. 21, No. 2, 2001, pp. 139–150. Alhaj, H.A., A.E. Massey, and R.H. McAllister-Williams, “Effects of DHEA Administration on Episodic Memory, Cortisol and Mood in Healthy Young Men: A Double- Blind, Placebo-Controlled Study,” Psychopharmacology, Vol. 188, 2006, pp. 541–551. American College of Sports Medicine, “Position Stand on the Use of Anabolic-Androgenic Steroids in Sports,” Medical Science and Sports Exercise, Vol. 19, 1984, pp. 13–18. American Institute of Biological Sciences (AIBS), Effects of Quercetin on Physical and Cognitive Performance and Human Health: A Status of the Science Review of the U.S. Army Research Institute of Environmental Medicine (USARIEM) and DoD Combat Feeding Directorate, Natick Soldier Research, Development and Engineering Center, Natick, Mass., Reston, Va., 2008, AIBS, Staff Representa- tive Liz Kirchner. American Medical Association, “Is the Patient at Increased Risk for Unsafe Driving?” Chapter 2, In: Physician’s Guide to Assessing and Counseling Older Drivers, NHTSA Report DOT-HS-809-647, U.S. Department of Transportation, National Highway Transportation Safety Administration, and the American Medical Association, Washington, D.C., 2003. Angrist, B., J. Rotrosen, D. Fleinberg, V. Merriam, and S. Gershon, “Dopaminergic Agonist Properties of Ephedrine: Theoretical Implications,” Psychopharmacology (Berlin), Vol. 55, No. 2, 1997, pp. 115–120. Anton-Fay, F., “On the Effect of Melatonin Upon the Human Brain: Its Possible Therapeutic Implications,” Life Science, Vol. 10, 1971, pp. 841–850. Anton-Fay, F., “Melatonin: Effects on Brain Function,” Advances in Biochemistry and Psychopharmacology, Vol. 11, 1974, pp. 315–424. Applegate, E.A. and L.E. Grivetti, “Search for the Competi- tive Edge: A History of Dietary Fads and Supplements,” Journal of Nutrition, Vol. 127, 1997, pp. 869S–873S. Arlt, W., F. Callies, and B. Allolio, “DHEA Replacement in Women with Adrenal Insufficiency—Pharmacokinetics, Bioconversion and Clinical Effects on Well-being, Sexu- ality and Cognition,” Endocrine Research, Vol. 26, 2000, pp. 505–511. Arnulf, I., et al., “Mid-Morning Tryptophan Depletion Delays REM Sleep Onset in Health Subjects,” Neuropsycho- pharmacology, Vol. 27, 2002, pp. 843–851. Astrup, A., S. Toubro, S. Cannon, P. Hein, and J. Madsen, “Thermogenic Synergism Between Ephedrine and Caffeine in Healthy Volunteers: A Double-Blind, Placebo-Controlled Study,” Metabolism, Vol. 40, 1991, pp. 323–329. Babkoff, H. and G.P. Krueger, “Use of Stimulants to Ameliorate the Effects of Sleep Loss During Sustained Performance,” Military Psychology, Vol. 4, No. 4, 1992, pp. 191–205. Babkoff, H., et al., “Pemoline and Methylphenidate: Interaction with Mood, Sleepiness and Cognitive Performance During 64-hours of Sleep Deprivation,” Military Psychology, Vol. 4, No. 4, 1992, pp. 235–265. Babu, K.M., R.J. Church, and W. Lewander, “Energy Drinks: The New Eye-opener for Adolescents,” Clinical Pediatric Emergency Medicine, Vol. 9, No. 1, 2008, pp. 35–42. Balderer, G. and A.A. Borbely, “Effect of Valerian on Human Sleep,” Psychopharmacology, Vol. 87, 1985, pp. 406–409. Baldock, M.R.J., Review of the Literature on Cannabis and Crash Risk, CASR Report Series Technical Report No. CASR010, Centre for Automotive Safety Research, South Australia, Australia, 2007. Balk, E.M., G. Raman, A. Tatsioni, M. Chung, J. Lau, and I.H. Rosenberg, “Vitamin B-6, B-12, and Folic Acid Supple- mentation and Cognitive Function: A Systematic Review of Randomized Trials,” Archives of Internal Medicine, Vol. 167, No. 1, 2007, pp. 21–30. Balkin, T.J., V.M. O’Donnell, N. Wesensten, U. McCann, and G. Belenky, “Comparison of the Daytime Sleep and Performance Effects of Zolpidem Versus Triazolam,” Psychopharmacology, Vol. 107, 1992, pp. 83–88. Ballas, C.A., D. Kim, C.F. Baldassano, and N. Hoeh, “Modafinil: Past, Present and Future,” Expert Review of Neurotherapeutics, Vol. 2, No. 4, 2002, pp. 449–457. Banderet, L.E. and H.R. Lieberman, “Treatment with Tyrosine, a Neurotransmitter Precursor, Reduces Environmental Stress in Humans,” Brain Research Bulletin, Vol. 22, 1989, pp. 756–762. Baranski, J. and R.A. Pigeau, “Self-monitoring Cognitive Per- formance During Sleep Deprivation: Effects of Modafinil, d-Amphetamine and Placebo,” Journal of Sleep Research, Vol. 6, 1997, pp. 84–91. Baranski, J.V., C. Cian, D. Esquivie, R.A. Pigeau, and C. Raphel, “Modafinil During 64 Hours of Sleep Depri- vation: Dose Related Effects on Fatigue, Alertness, and Cognitive Performance,” Military Psychology, Vol. 10, 1998, pp. 173–193. Baranski, J., et al., Assessment of Potential Physical and Cognitive Aids for Performance Enhancement of Conven- APPENDIX D References

tional and Special Operations, 3rd ed., TTCP Technical Report No. HUM-01-11, Group HUM—Human Resources and Performance, Technical Panel 8, The Technical Co- operation Program (TTCP), Toronto, ON, Canada, 2001. [The report is also listed alphabetically under the entry: The Technical Cooperation Program (TTCP 2001)]. Baranski, J.V., R. Pigeau, P. Dinich, and I. Jacobs, “Effects of Modafinil on Cognitive and Meta-Cognitive Performance,” Human Psychopharmacology, Vol. 19, 2004, pp. 323–332. Batejat, D.M. and D.P. Lagarde, “Naps and Modafinil as Countermeasures for the Effects of Sleep Deprivation on Cognitive Performance,” Aviation, Space and Environ- mental Medicine, Vol. 70, 1999, pp. 493–498. Barkley, R.A., K.R. Murphy, T. O’Connell, and D.F. Connor, “Effects of Two Doses of Methylphenidate on Simulator Driving Performance in Adults with Attention Deficit Hyperactivity Disorder,” Journal of Safety Research, Vol. 36, 2005, pp. 121–131. Bates, T., G. Mangan, C. Stough, and P. Corballis, “Smoking, Processing Speed and Attention in a Choice Reaction Time Task,” Psychopharmacology, Vol. 120, 1995, pp. 209–212. Baum, M. and M. Weiss, “The Influence of a Taurine Con- taining Drink on Cardiac Parameters Before and After Exercise Measured by Echocardiography,” Amino Acids, Vol. 20, No. 1, 2001, pp. 75–82. Beirness, D.J., H.M. Simpson, and A.F. Williams, “The Role of Cannabis and Benzodiazepines in Motor Vehicle Crashes,” In: Drugs and Traffic: A Symposium, Woods Hole, Mass., June 20–21, 2005, pp. 16–26. Transportation Research Cir- cular No. E-C096, Transportation Research Board Commit- tee on Alcohol, and Other Drugs, Transportation Research Board of the National Academies, Washington, D.C., 2005. Belland, K. and C. Bissell, “Operation Southern Watch, Naval Aviation Continuous/Sustained Operations,” Aviation, Space and Environmental Medicine, Vol. 65, 1994, p. 561. Bell, D.G. and I. Jacobs, “Combined Caffeine and Ephedrine Ingestion Improves Run Times of Canadian Forces Warrior Test,” Aviation, Space and Environmental Medicine, Vol. 70, 1999, pp. 325–329. Bell, D.G., I. Jacobs, T.M. McLellan, M. Miyazaki, and C.M. Sabistion, “Thermal Regulation in Heat During Exercise After Caffeine and Ephedrine Ingestion,” Avia- tion, Space and Environmental Medicine, Vol. 70, 1999, pp. 583–588. Bell, S.L., R.C. Taylor, E.G. Singleton, J.E. Henningfield, and S.J. Heishman, “Smoking After Nicotine Deprivation Enhances Cognitive Performance and Decreases Tobacco Craving in Drug Abusers,” Nicotine and Tobacco Research, Vol. 1, 1999, pp. 45–52. Bell, D.G., et al., Effects of Ingesting a Combination of Caffeine and Ephedrine on 5.3-km Load March, a 2.9-km Run, Marksmanship and Cognitive Performance, TTCP Report HUM/01/04, Defence and Civil Institute of Environ- mental Medicine, Toronto, ON, Canada, 2001. Bempong, D.K. and P.J. Houghton, “Dissolution and Absorp- tion of Caffeine from Guarana,” Journal of Pharmacology, Vol. 44, No. 9, 1992, pp. 769–771. 94 Bempong, D.K., P.J. Houghton, and K. Steadman, “The Xanthine Content of Guarana and its Preparations,” Inter- national Journal of Pharmacology, Vol. 31, No. 3, 1993, pp. 175–181. Benignus, V.A., “Effects of Atmospheric Mix and Toxic Fumes on Military Performance,” Chapter 17, In: Handbook of Military Psychology, R. Gal and A.D. Mangelsdorff, Eds., John Wiley and Sons, Ltd., Chichester, England, 1991, pp. 313–333. Benzer, T.I., Toxicity, Gamma-Hydroxybutyrate, eMedicine, 2007 [Online]. Available: http://www.emedicine.com/ emerg/topic848.htm. Berghaus, G. and H. Grass, “Concentration-effect Relationship with Benzodiazepine Therapy,” In: Proceedings of the 14th International Conference on Accidents, Drugs and Traffic Safety (ICADTS—T97), Centre d Etudes et de Recherches en Medecine du Trafic (CERMIT), Annecy, France, 1997, pp. 705–709. Berghaus, G., H.P. Krûger, and M. Vollrath, “Beeintrachtigung Fahrrelevanter Leistungen nach Rauchen von Cannabis und Alcoholconsum. Eine Vergleichende Metaanalyse Exper- imenteller Studien,” In: Cannabis im Strassenverkehr, G. Berghaus and H.P. Krûger, Eds., Gustav Fisher Verlag, Stuttgart, Germany, 1998, pp. 99–111. Berghaus, G., E. Schultz, and A. Szegedi, “Cannabis und Fahrt u Chtigkeit. Ergebnisse der Experimentelle Fors- chung,” In: Cannabis im Strassenverkehr, G. Berghaus and H.P. Krûger, Eds., Gustav Fisher Verlag, Stuttgart, Germany, 1998, pp. 73–97. Bertrand, G. and P. Carneiro, “The Presence of Caffeine and Theobromine in the Organs of Paullinia Cupana,” Bulletin of Science of Pharmacology, Vol. 39, 1932, pp. 273–278 Betts, T., D. Markman, S. Debenham, D. Mortiboy, and T. McKevitt, “Effects of Two Antihistamine Drugs on Actual Driving Performance,” British Medical Journal of Clinical Research, Vol. 288, 1984, pp. 281–282. Biggs, S., et al., “Perception of Simulated Driving Perfor- mance After Sleep Deprivation Restriction and Caffeine,” Journal of Psychosomatic Research, Vol. 63, No. 6, 2007, pp. 573–577. Bischoff, E., “Vardenafil Preclinical Trial Data: Potency, Pharmacodynamics, Pharmacokinetics and Adverse Events,” International Journal of Impotence Research, Vol. 16, Supplement 1, 2004, pp. S34–S37. Bishop, C., T. Roehrs, L. Rosenthal, and T. Roth, “Alerting Effects of Methylphenidate Under Basal and Sleep- Deprived Conditions,” Experimental Clinical Psychophar- macology, Vol. 5, 1997, pp. 344–352. Bittencourt, L.R.A., et al., “Placebo and Modafinil Effect on Sleepiness in Obstructive Sleep Apnea,” Progress in Neuro- psychopharmacology and Biological Psychiatry, Vol. 32, No. 2, 2008, pp. 552–559. Blanke, R.V., et al., “Consensus Development Panel Report: Drug Concentrations and Driving Impairment,” Journal of the American Medical Association, Vol. 254, 1985, pp. 2618–2621.

95 Blomstrand, E., “Influence of Ingesting a Solution of BCAA on Perceived Exertion During Exercise,” Acta Physiology Scandinavian, Vol. 159, No. 1, 1997, pp. 41–49. Bonnet, M.H., “Use of Prophylactic Naps Versus Caffeine to Maintain Alertness During Periods of Sleep Loss,” Presentation at the Institute of Medicine Workshop on Caffeine Formulations for Sustainment of Mental Task Performance during Military Operations, Feb. 2–3, 1999, Committee on Military Nutrition Research, Washington, D.C., 1999. Bonnet, M.H. and D.L. Arand, “The Use of Prophylactic Naps and Caffeine to Maintain Performance During a Continuous Operation,” Ergonomics, Vol. 37, 1994, pp. 1009–1020. Bordeleau, R., D.G. Bell, I. Jacobs, and J. Zamecnik, Caffeine, Ephedrine and Their Combination: Effects on Blood Pressure and Heart Rate, DCIEM Technical Report No. 1999-069, Defence and Civil Institute of Environmental Medicine, Toronto, ON, Canada, Aug. 1999. Borrillo, D.J., “Dangers of Viagra Use in Pilots,” Federal Air Surgeon Medical Bulletin, Vol. 98, No. 3, 1998, p. 1. Botch, S.R. and R.D. Johnson, Drug Usage in Pilots Involved in Aviation Accidents Compared with Drug Usage in the General Population: From 1990 to 2005, FAA CAMI Technical Report No. DOT-FAA-AM-08-10, Civil Aero- space Medical Institute, Federal Aviation Administration, Oklahoma City, Okla., 2008. Bower, E.A., J.L. Moore, M. Moss, K.A. Selby, M. Austin, and S. Meeves, “The Effects of Single-dose Fexofenadine, Diphenhydramine, and Placebo on Cognitive Performance in Flight Personnel,” Aviation, Space, and Environmental Medicine, Vol. 74, 2003, pp. 145–152. Bowers, L.D., “Oral Dehydroepiandrosterone Supplementa- tion Can Increase the Testosterone/Epitestosterone Ratio,” Clinical Chemistry, Vol. 45, 1999, pp. 295–296. Brick, J., “Standardization of Alcohol Calculations in Research,” Alcohol Clinical Experimental Research, Vol. 30, No. 8, pp. 1276–1287. Brumaghim, J.T., R. Klorman, J. Strauss, J.D, Levine, and M.G. Goldstein, “Does Methylphenidate Affect Informa- tion Processing? Findings from Two Studies on Perfor- mance and P3b Latency,” Psychophysiology, Vol. 24, 1987, pp. 361–373. Bucci, L., Nutrients as Ergogenic Aids for Sports and Exercise, CRC Press, Taylor and Francis, Ltd., Boca Raton, Fla., 1993. Buguet, A., A. Montmayeur, R. Pigeau, and P. Naithoh, “Modafinil, d-Amphetamine, and Placebo During 64 Hours of Sustained Mental Work. II. Effects on Two Nights of Recovery Sleep,” Journal of Sleep Research, Vol. 4, 1995, pp. 229–241. Buguet, A., D.E. Moroz, and M.W. Radomski, “Modafinil— Medical Considerations for Use in Sustained Operations,” Aviation, Space and Environmental Medicine, Vol. 74, 2003, pp. 659–663. Burns, M., “Cocaine Effects on Performance,” In: Alcohol, Drugs and Traffic Safety, T92-Band 2, H. Utzelmann, G. Berfhaus, and G. Ktoj, Eds., Verlag TUV Rheinland, Cologne, Germany, 1993, pp. 612–619. Buysse, D.J., P.K. Schweitzer, and D.E. Moul, “Clinical Pharmacology of Other Drugs Used as Hypnotics,” Chapter 37, In: Principles and Practice of Sleep Medicine, M.H. Kryger, T. Roth, and W.C. Dement, Eds., 4th ed., Elsevier Saunders, Philadelphia, Pa., 2005, pp. 452–467. Caldwell, J.A., “Understanding and Managing Fatigue in Aviation,” In: Handbook of Operator Fatigue, P.A. Desmond, G. Matthews, and P.A. Hancock, Eds., Ashgate Publishing, Burlington, Vt., in press. Caldwell, J.A. and J.L. Caldwell, “An In-flight Investigation of the Efficacy of Dextroamphetamine for Sustaining Helicopter Pilot Performance,” Aviation, Space, and Envi- ronmental Medicine, Vol. 68, 1997, pp. 1073–1080. Caldwell, J.A. and J.L. Caldwell, “Comparison of the Effects of Zolpidem-induced Prophylactic Naps to Placebo Naps and Forced Rest Periods in Prolonged Work Schedules,” Sleep, Vol. 21, No. 1, 1998, pp. 79–90. Caldwell, J.A. and J.L. Caldwell, Fatigue in Aviation: A Guide to Staying Awake at the Stick, Ashgate Publishing Co., Burlington, Vt., 2003. Caldwell, J.A. and J.L. Caldwell, “Fatigue in Military Aviation: An Overview of U.S. Military-approved Pharmacological Countermeasures,” Aviation, Space, and Environmental Medicine, Vol. 76, No. 7, Section II, 2005, pp. C39–C51. Caldwell, J.A., J.L. Caldwell, J.S. Crowley, and H.D. Jones, “Sustaining Helicopter Pilot Performance with Dexedrine During Periods of Sleep Deprivation,” Aviation, Space and Environmental Medicine, Vol. 66, 1995, pp. 930–937. Caldwell, J.A., J.L. Caldwell, and J.S. Crowley, “Sustaining Female Helicopter Pilot Performance with Dexedrine During Sustained Operations,” International Journal of Aviation Psychology, Vol. 7, 1997, pp. 15–36. Caldwell, J.A., J.L. Caldwell, N.K. Smythe, and K.K. Hall, “A Double-blind, Placebo-controlled Investigation of the Efficacy of Modafinil for Sustaining the Alertness and Performance of Aviators: A Helicopter Simulator Study,” Psychopharmacology, Vol. 150, 2000, pp. 272–282. Caldwell, J.A., N.K. Smythe, P.A. Leduc, and J.L. Caldwell, “Efficacy of Dextroamphetamine for the Maintenance of Aviator Performance During 64 Hours of Sustained Wake- fulness,” Aviation, Space, and Environmental Medicine, Vol. 71, 2000, pp. 7–18. Caldwell, J.A., et al., The Efficacy of Modafinil for Sustaining Alertness and Simulator Flight Performance in F-117 Pilots During 37 Hours of Continuous Wakefulness, Technical Report No. AFRL-HE-BR-TR-2004-0003, Human Effec- tiveness Division, U.S. Air Force Research Laboratory, Brooks City Base, Tex., 2004. Caldwell, J.A., M.M. Mallis, J.L. Caldwell, M.A. Paul, J.C. Miller, and D.F. Neri, “Fatigue Countermeasures in Aviation,” Aviation, Space, and Environmental Medicine, Vol. 80, No. 1, 2009, pp. 29–59. Caldwell, J.L., B.F. Prazinko, T. Rowe, D. Norman, K.K. Hall, and J.A. Caldwell, “Improving Daytime Sleep with Temazepam as a Countermeasure for Shift Lag,” Aviation, Space and Environmental Medicine, Vol. 74, 2003, pp. 153–163.

Calfee, R. and P. Fadale, “Popular Ergogenic Drugs and Supplements in Young Athletes,” Pediatrics, Vol. 117, No. 3, 2006, pp. 577–589. Campbell, S.S. and R.J. Broughton, “Rapid Decline in Body Temperature Before Sleep: Fluffing the Physiological Pillow?” Chronobiology International, Vol. 11, No. 2, 1994, pp. 126–131. Canfield, D.V., G.J. Salazar, R.J. Lewis, and J.E. Whinnery, Comparison of Pilot Medical History and Medications Found in Postmortem Specimens, FAA CAMI Technical Report No. DOT-FAA-AM-06-12, Civil Aerospace Medical Institute, Federal Aviation Administration, Oklahoma City, Okla., 2006. Canter, P.H. and E. Ernst, “Ginkgo Biloba Is Not a Smart Drug: An Updated Systematic Review of Randomized Clinical Trials Testing the Nootropic Effects of G. Biloba Extracts in Healthy People,” Human Psychopharmacology, Vol. 22, No. 5, 2007, pp. 265–278. Cardinal, B.J. and H.J. Engels, “Ginseng Does Not Enhance Psychological Well-Being in Healthy, Young Adults: Results of a Double-Blind, Placebo-Controlled, Random- ized Clinical Trial,” Journal of the American Dietetic Asso- ciation, Vol. 101, No. 6, 2001, pp. 655–660. Carskadon, M.A., Ed., Encyclopedia of Sleep and Dreaming, Macmillan Publishing, Co., New York, N.Y., 1993. Carter, W.E., Ed., Cannabis in Costa Rica: A Study of Chronic Marijuana Use, Institute for the Study of Human Issues, Philadelphia, Pa., 1980. Chagan, I. and L.A. Cicero, “Zaleplon: A Possible Advance in the Treatment of Insomnia,” Pharmacy and Thera- peutics, Vol. 24, 1999, pp. 590–599. Chaturvedi, A.K., K.J. Craft, D.V. Canfield, and J.E. Whinnery, “Toxicological Findings from 1587 Civil Aviation Accident Pilot Fatalities, 1999–2003,” Aviation, Space and Environ- mental Medicine, Vol. 76, No. 12, 2005, pp. 1145–1150. Chen, Z.-Y. and W.P. Fong, “Hypolipidemic Activity of Green Tea Epicatechins,” Paper No. 17, In: Caffeinated Beverages: Health Benefits, Physiological Effects and Chemistry, T.H. Parliament, C.-T. Ho, and P. Schieberle, Eds. American Chemical Society Symposium Series No. 754, Oxford University Press, Oxford, U.K., 2000. Chepkova, A.N., N. Doreulee, Y. Yanovsky, D. Mukho- padhyay, H.L. Haas, and O.A. Sergeeva, “Long-lasting Enhancement of Corticostriatal Neurotransmission by Taurine,” European Journal of Neuroscience, Vol. 16, No. 8, 2002, pp. 1523–1530. Chesher, G.B., “Cannabis and Road Safety: An Outline of Research Studies to Examine the Effects of Cannabis on Driving Skills and Actual Driving Performance,” In: The Effects of Drugs (Other Than Alcohol) on Road Safety, Road Safety Committee, Parliament of Victoria Road Safety Committee, Melbourne, Australia, 1995, pp. 67–96. Clarkson, P.M., “Antioxidants and Physical Performance,” Critical Reviews in Food Science and Nutrition, Vol. 35, Nos. 1 and 2, 1995, pp. 131–141. Clauson, K.A., K.M. Shields, C.E. McQueen, and N. Persad, “Safety Issues Associated with Commercially Available 96 Energy Drinks,” Journal of American Pharmacological Association, Vol. 48, No. 3, 2003, pp. e55–e63. Clayton, A.B., “The Effects of Psychotropic Drugs upon Driving-related Skills,” Human Factors, Vol. 18, No. 3, 1976, pp. 241–252. Cohen, G.B., “The Analysis of Coffee Phenols and Phenolic Acids,” Paper No. 36, In: Caffeinated Beverages: Health Benefits, Physiological Effects and Chemistry, T.H. Parlia- ment, C.-T. Ho, and P. Schieberle, Eds., American Chemical Society Symposium Series No. 754, Oxford University Press, Oxford, U.K., 2000. Cole, K.J., D.L. Costil, R.D. Starling, B.H. Goodpaster, S.W. Trapper, and W.J. Fink, “Effect of Caffeine Ingestion on Perception of Effort and Subsequent Work Production,” International Journal of Sports Nutrition, Vol. 6, 1996, pp. 14–23. Colrain, I.M., J. Trinder, and G.E. Swan, “The Impact of Smoking Sensations on Central and Autonomic Nervous System Activity During Sleep: Review, Synthesis, and Recommendations,” Nicotine and Tobacco Research, Vol. 6, No. 6, 2004, pp. 913–925. Comperatore, C.A. and G.P. Krueger, “Circadian Rhythm Desynchronosis, Jet Lag, Shift Lag, and Coping Strategies,” In: Occupational Medicine: State of the Art Reviews, A.J. Scott, Ed., Hanley and Belfus, Inc., Philadelphia, Pa., Vol. 5, No. 2, 1990, pp. 323–341. Connors, C.K. and E. Taylor, “Pemoline, Methylphenidate and Placebo in Children with Minimal Brain Dysfunction,” Archives of General Psychiatry, Vol. 37, 1980, pp. 922–930. Coons, H.W., et al., “Effect of Methylphenidate on Young Adults’ Vigilance and Event-related Potentials,” Electro- encephalography and Clinical Neurophysiology, Vol. 51, 1981, pp. 373–387. Cramer, H., “Melatonin and Sleep,” In: Sleep, L. Popovicu and G. Asgian, Eds., Karger, Basel, Switzerland, 1980, pp. 204–210. Cramer, H., J. Rudolph, and K. Kendel, “On the Effects of Melatonin on Sleep and Behavior in Man,” Advances in Biochemical Psychopharmacology, Vol. 11, 1974, pp. 187–191. Craft, R., The Large Truck Crash Causation Study, Technical Report No. FMCSA-RRA-07-017, Analysis Division, Federal Motor Carrier Safety Administration, U.S. Depart- ment of Transportation, Washington, D.C., 2007 [Online]. Available: http:www.fmcsa.dot.gov/facts-research/research- technology/analysis/FMCSA-RRA-07-017.htm. Croft, R.J., A.J. Mackay, A.T. Mills, and J.G. Gruzelier, “The Relative Contributions of Ecstasy and Cannabis to Cognitive Impairment,” Psychopharmacology, Vol. 153, No. 3, 2001, pp. 373–379. Cui, J., M. Garle, P. Eneroth, and I. Bjorkhem, “What Do Commercial Ginseng Preparations Contain?” Lancet, Vol. 344, 1994, p. 134. Cummings, S.R., B. Hansen, R.J. Richard, M.J. Stein, and T.J. Coates, “Internists and Nicotine Gum,” Journal of the American Medical Association, Vol. 260, 1988, pp. 1565–1569.

97 Czeisler, C.A., et al., “Modafinil for Excessive Sleepiness Associated with Shiftwork Sleep Disorder,” New England Journal of Medicine, Vol. 353, 2005, pp. 476–486. Davis, G.J., What Every Supervisor Should Know About Alcohol, ATA Technical Report, The American Trucking Associations, Alexandria, Va., 1996. Dawson, D. and N. Encel, “Melatonin and Sleep in Humans,” Journal of Pineal Research, Vol. 15, 1993, pp. 1–12. DeGier, H., “Medicinal Drugs: Critical Review of Present Knowledge and Statements for Discussion,” In: Transporta- tion Research Circular No. E-C096: Drugs and Traffic: A Symposium, Transportation Research Board Committee on Alcohol and Other Drugs, Woods Hole, Mass., June 20–21, 2005, pp. 68–77. DeGier, J.J., B.J. Hart, F.A Nelemans, and H. Bergman, “Psychomotor Performance and Real Driving Performance of Outpatients Receiving Diazepam,” Psychopharmacology, Vol. 73, 1981, pp. 340–347. DeGrandpre, R., Ritalin Nation, W.W. Norton Press, New York, N.Y., 1999. Deijen, H.B., C.J. Wientjes, H.F. Vullinghs, P.A. Cloin, and J.J. Lamgeford, “Tyrosine Improves Cognitive Performance and Reduces Blood Pressure in Cadets after One Week of a Combat Training Course,” Brain Research Bulletin, Vol. 48, No. 2, 1999, pp. 203–209. DeMey, C., “Opportunities for the Treatment of Erectile Dysfunction by Modulation of the NO Axis-—Alternatives to Sildenafil Citrate,” Current Medical Research and Opin- ion, Vol. 14, 1998, pp. 187–202. DeSciscio, P., A. Prabhu, M. Worthley, R. Roberts-Thomson, P. Sanders, and S. Willoughby, “Acute Effects of Red Bull on Platelet and Endothelial Function,” Heart, Lung and Circulation, Vol. 17, Supplement 3, 2008, pp. S23–S24. DeValck, E., and R. Cluydts, “Slow-response Caffeine as a Countermeasure to Driver Sleepiness Induced by Par- tial Sleep Deprivation,” Sleep Research, Vol. 10, 2001, pp. 203–209. DeValck, E., E. DeGroot, and R. Cluydts, “Effects of Slow- release Caffeine and a Nap on Driving Simulator Perfor- mance after Partial Sleep Deprivation,” Perceptual and Motor Skills, Vol. 96, No. 1, 2003, pp. 67–78. Donath, F., S. Quispe, K. Diefenbach, A. Maurer, I. Fietze, and I. Roots, “Critical Evaluation of the Effect of Valerian Extract on Sleep Structure and Sleep Quality,” Pharmaco- psychiatry, Vol. 33, No. 2, 2000, pp. 47–53. Drake, E.B., et al., “Associations Between Circulating Sex Steroid Hormones and Cognition in Normal Elderly Women,” Neurology, Vol. 54, 2000, pp. 599–603. Duke, J.A., CRC Handbook of Medicinal Herbs, CRC Press, Boca Raton, Fla., 1985. Durlach, P.J., “The Effect of Low Dose Caffeine on Cognitive Performance,” Psychopharmacology, Vol. 140, 1998, pp. 116–119. Ebert, B., K.A. Wafford, and S. Deacon, “Treating Insomnia: Current and Investigational Pharmacological Approaches,” Pharmacological Therapy, Vol. 112, 2006, pp. 612–629. Elie, R., E. Ruther, I. Farr, G. Emilien, and E. Salinas, “Sleep Latency Is Shortened During 4 Weeks of Treatment with Zaleplon, a Novel Non-benzodiazepine Hypnotic,” Journal of Clinical Psychiatry, Vol. 60, 1999, pp. 536–544. Engles, H.J., J.M. Said, and J.C. Wirth, “Failure of Chronic Ginseng Supplementation to Affect Work Performance and Energy Metabolism in Healthy Adult Females,” Nutrition Research, Vol. 16, 1996, pp. 1295–1305. Engels, H.J., M.M. Fahlman, and J.C. Wirth, “Ginseng Does Not Enhance Physical Performance,” Medicine and Science in Sports and Exercise, Vol. 35, No. 4, 2003, pp. 690–696. Epstein, D.H., K. Silverman, J.E. Henningfield, and K.L. Preston, “Low-dose Oral Cocaine in Humans: Acquisition of Discrimination and Time-course of Effects,” Behavioral Pharmacology, Vol. 10, 1999, pp. 531–542. Ernst, M., S.J, Heishman, L. Spurgeon, and E.D. London, “Smoking History and Nicotine Effects on Cognitive Performance,” Neuropsychopharmacology, Vol. 25, 2001, pp. 313–319. Federal Highway Administration (FHWA), Conference on Psychiatric Disorders and Commercial Drivers, Office of Motor Carriers Technical Report FHWA-MC-91-006, FHWA, U.S. Department of Transportation, Washington, D.C., May 1991. Federal Highway Administration (FHWA), Conference on Neurological Disorders and Commercial Drivers, Office of Motor Carriers Technical Report FHWA-MC-88-042, [online]. FHWA, U.S. Department of Transportation, Wash- ington, D.C., July 1988 [online]. Available: http://www. fmcsa.dot.gov/documents/neuro.pdf [accessed Mar. 10, 2010]. Federal Motor Carrier Safety Administration (FMCSA), Med- ical Examiner Handbook, FMCSA, U.S. Department of Transportation, Washington, D.C., n.d. [Online]. Available in PDF format at www.fmcsa.dot.gov and http://nrcme. fmcsa.dot.gov/mehandbook/MEhandbook.htm. Ferreria, S.E., T. deMello, S. Pompeia, and M.L.O deSouza- Formigoni, “Effects of Energy Drink Ingestion on Alcohol Intoxication,” Alcoholism: Clinical and Experimental Research, Vol. 30, No. 4, pp. 598–605. Field, H.L., D.A. Monti, J.M. Greeson, and E. Kunkel, “St. John’s Wort,” International Journal of Psychiatry and Medicine, Vol. 30, No. 3, 2000, pp. 203–219. File, S.E., E. Fluck, and C. Fernandes, “Beneficial Effects of Glycine (Bioglycin) on Memory and Attention in Young and Middle-aged Adults,” Journal of Clinical Psycho- pharmacology, Vol. 19, No. 6, pp. 506–512. Fischman, M.W. and C.R. Schuster, “Cocaine Effects in Sleep-deprived Humans,” Psychopharmacology, Vol. 72, 1980, pp. 1–8. Fitzpatrick, P., R. Klorman, J.T. Brumaghim, and R.W. Keefover, “Effects of Methylphenidate on Stimulus Eval- uation and Response Processes: Evidence from Performance and Event-related Potentials,” Psychophysiology, Vol. 25, 1998, pp. 292–304. Fone, K.C. and D.J. Nutt, “Stimulants: Use and Abuse in the Treatment of Attention Deficit Hyperactivity Disorder,”

Current Opinion in Pharmacology, Vol. 5, No. 1, 2005, pp. 87–93. Foskett, A., A. Ali, and N. Gant, “Caffeine Enhances Cognitive Function and Skill Performance During Simulated Soccer Activity,” International Journal of Sport Nutrition and Exercise Metabolism, Vol. 18, No. 4, 2008. Foulds, J., J. Stapleton, J. Swettenham, N. Bell, K. McSorley, and M.A.H. Russell, “Cognitive Performance Effects of Subcutaneous Nicotine in Smokers and Never-smokers,” Psychopharmacology, Vol. 127, 1996, pp. 31–38. Friedl, K.E., “Effect of Anabolic Steroid Use on Body Compo- sition and Physical Performance,” Chapter 5, In: Anabolic Steroids in Sport and Exercise, 2nd ed., C.E. Yesalis, Ed., Human Kinetics Publishers, Champaign, Ill., 2002a, pp. 139–174. Friedl, K.E., “Effects of Anabolic Steroids on Physical Health,” Chapter 6, In: Anabolic Steroids in Sport and Exercise, 2nd ed., C.E. Yesalis, Ed., Human Kinetics Publishers, Champaign, Ill., 2002b, pp. 175–224. Fry, J., M. Scharf, R. Mangano, and M. Fujimori, “Zaleplon Improves Sleep Without Producing Rebound Effects in Outpatients with Insomnia,” International Clinical Psycho- pharmacology, Vol. 15, 2000, pp. 141–152. Galduroz, J.C. and E.A. Carlini, “Acute Effects of Paullinia Cupana, ‘Guarana’ on the Cognition of Normal Volunteers,” Revista Paulista de Medicine [Rev. Paul. Med.], Vol. 112, No. 3, 1994, pp. 607–611. Galduroz, J.C. and E.A. Carlini, “The Effects of Long- term Administration of Guarana on the Cognition of Normal, Elderly Volunteers,” Revista Paulista de Medicine [Rev. Paul. Med.], Vol. 114, 1996, pp. 1073–1078. Geha, R.S. and E.O. Meltzer, “Desloratadine: A New, Non-sedating Oral Antihistamine,” Journal of Allergy and Clinical Immunology, Vol. 107, 2001, pp. 751–762. Gelfand, S., L. Clarke, E.W. Herbert, D. Gelfand, and E.D. Holmes, “Magnesium Pemoline: Stimulant Effects on Performance of Fatigued Subjects,” Clinical Pharmaco- logical Therapy, Vol. 9, 1968, pp. 56–60. Gengo, F.M., “Reduction of the Central Nervous System Adverse Effects Associated with Antihistamines in the Management of Allergic Disorders: Strategies and Progress,” Journal of Allergy and Clinical Immunology, Vol. 98, No. 6, 1996, pp. S319–S325. Gengo, F.M. and C. Gabos, “Antihistamines, Drowsiness, and Psychomotor Impairment: Central Nervous System Effect of Cetirizine,” Annals of Allergy, Vol. 59, 1987, pp. 53–57. Gengo, F. and C. Manning, “A Review of the Effects of Anti- histamines on Mental Processes Related to Automobile Driving,” Journal of Allergy and Clinical Immunology, Vol. 86, 1990, pp. 1034–1039. Gengo, F., C. Gabos, and J.K. Miller, “The Pharmaco- dynamics of Diphenhydramine Induced Drowsiness and Changes in Mental Performance,” Clinical Pharmacology Therapy, Vol. 45, 1989, pp. 15–21. Gertler, J., S. Popkin, D. Nelso, and K. O’Neil, TCRP Synthesis of Transit Practice 81: Toolbox for Transit Operator 98 Fatigue, Transportation Research Board, National Research Council, Washington, D.C., 2002. Ghoneim, M.M., S.P. Mewaldt, and J.W. Thatcher, “The Effect of Diazepam and Fentanyl on Mental, Psychomotor and Electroencephalographic Functions and Their Rate of Recovery,” Psychopharmacology, Vol. 44, No. 1, 1975, pp. 61–66. Gilbert, G.J., “Ginkgo Biloba.” Neurology, Vol. 48, 1997, p. 1137. Gibson, J., D.J. Mascord, and G.A. Starmer, The Effects of Caffeine on the Development of Fatigue in a Prolonged Driving-related Task, Department of Pharmacology, Uni- versity of Sydney, New South Wales, Australia, 2006. Gopinathan, P.M., G. Pichan, and W.M. Sharma, “Role of Dehydration in Heat Stress-induced Variations in Mental Performance,” Archives of Environmental Health, Vol. 43, 1988, pp. 15–17. Gore, R.K., T.S. Webb, and E.D.A. Hermes, “Fatigue and Stimulant Use in Military Fighter Aircrew During Combat Operations,” Aviation, Space and Environmental Medicine, Vol. 81, No. 8, 2010, pp. 719–727. Government Accounting Office (GAO), Dietary Supplements: FDA Should Take Further Actions to Improve Oversight and Consumer Understanding, GAO Highlights Report No. GAO-09-250, GAO, Washington, D.C., 2009. Grady, S., D. Aeschbach, K.P. Wright, and C.A. Czeisler, “Effect of Modafinil on Impairments in Neurobehavioral Performance and Learning Associated with Extended Wakefulness and Circadian Misalignment,” Neuropsycho- pharmacology, Vol. 35, 2010, pp. 1910–1920. Graziano, K., K. Hegmann, H. Leaman, and E. Wood, “A Summary of Recommendations Regarding the Use of Medications in Commercial Drivers,” abstract presented at the American Occupational Health Conference, Apr. 30– May 3, American College of Occupational and Environ- mental Medicine, Elk Grove Village, Ill., 2011. Greenblatt, D.J., G. Zammit, J. Harmatz, and E. Legangneux, “Zolpidem Modified-release Demonstrates Sustained and Greater Pharmacodynamic Effects from 3 to 6 Hours Post- dose as Compared with Standard Zolpidem in Healthy Adult Subjects” [abstr.], Sleep, Vol. 28, supplement, 2005, p. A245. Greenwood, M.R.C. and M. Oria, Eds., Use of Dietary Sup- plements by Military Personnel, Report of the Institute of Medicine of the National Academies, Committee on Military Nutrition Research (IOM-CMNR), National Academies Press, Washington, D.C., 2008. Gross, T.M., M.E. Jarvik, and M.R. Rosenblatt, “Nicotine Abstinence Produces Content-specific Stroop Interference,” Psychopharmacology (Berl), Vol. 127, 1993, pp. 31–38. Grosz, A. and A. Szatmari, “The History, Ingredients and Effects of Energy Drinks,” Orvosi Hetilap, Vol. 149, No. 47, 2008, pp. 2237–2244 [in Hungarian]. Gruberg, R., Drug and Alcohol Testing Survey: 2005 Results, Technical Report No. FMCSA RRA-07-014, Office of Research and Analysis Brief, Federal Motor Carrier Safety

99 Administration, U.S. Department of Transportation, Wash- ington, D.C., 2007. Gruenwald, J., T. Brendler, and C. Jaenicke, Eds., “Passiflora Incarnate,” PDR for Herbal Medicines, Medical Economics Co., Montvale, N.J., 1998, pp. 1015–1016. Gustavsen, I., J.G. Bramnes, S. Skurtveit, A. Engeland, I. Neutel, and J. Morland, “Road Traffic Accident Risk Related to Prescriptions of the Hypnotics Zopiclone, Zolpi- dem, Flunitrazepam and Nitrazepam,” Sleep Medicine, Vol. 9, No. 8, 2008, pp. 818–822. Halas, C.J., “Eszopiclone,” American Journal of Health and Systemic Pharmacology, Vol. 63, No. 1, 2006, pp. 41–48. Haller, C.A. and N.L. Benowitz, “Adverse Cardiovascular and Central Nervous System Events Associated with Dietary Supplements Containing Ephedra Alkaloids,” New England Journal of Medicine, Vol. 343, 2000, pp. 1833–1838. Hara, Y., “Health Benefits of Green Tea Catechins: Improve- ment of Intestinal Conditions,” Paper No. 18, In: Caffeinated Beverages: Health Benefits, Physiological Effects and Chemistry, T.H. Parliament, C.-T. Ho, and P. Schieberle, Eds., American Chemical Society Symposium Series No. 754, Oxford University Press, Oxford, U.K., 2000. Hart, J. and J. Wallace, “The Adverse Effects of Amphe- tamines,” Clinical Toxicology, Vol. 8, No. 2, 1975, pp. 179–190. Hartenbaum, N., Commercial Driver Medical Examiner (CDME) Self-assessment, 5th ed., American College of Occupational and Environmental Medicine, Elk Grove Village, Ill., 2008. Hartenbaum, N., M.G. Holland, A.J. Osbahr, M.B. Riba, and R. Swotinsky, “Expert Panel Commentary and Recom- mendations: Licit Schedule II Drug Use and Commercial Motor Vehicle Driver Safety,” presented to Federal Motor Carrier Safety Administration, Dec. 9, 2006, and Oct. 21, 2006 [Online]. Available: http://www.fmcsa.dot.gov/rules- regulations/topics/mep/mep-reports.htm. Hassmen, P., E. Blomstrand, B. Ekblom, and E.A. Newsholme, “BCAA Supplementation During 30km Competitive Run: Mood and Cognitive Performance,” Nutrition, Vol. 10, No. 5, 1994, pp. 405–410. Heatherly, S.V., R.C. Hayward, J. Hill, H.J. Smit, K.F. Cater, and P.J. Rogers, “Effects of Caffeine and Caffeine With- drawal on Simulated Driving Performance,” Journal of Psychopharmacology, Supplement, Vol. 18, No. 3, 2004, p. A29. Heishman, S.J., “What Aspects of Human Performance Are Truly Enhanced by Nicotine?” Editorial, Addiction, Vol. 93, No. 3, 1998, pp. 317–320. Heishman, S.J., M.A. Huertis, J.E. Henningfield, and E.J. Cone, “Acute and Residual Effects of Marijuana: Pro- files of Plasma THC Levels, Physiological, Subjective, and Performance Measures,” Pharmacology Biochemistry and Behavior, Vol. 37, 1990, pp. 561–565. Heishman, S.J., R.C. Taylor, and J.E. Henningfield, “Nicotine and Smoking: Review of Effects on Human Performance,” Experimental and Clinical Psychopharmacology, Vol. 2, 1994, pp. 345–395. Heishman, S.J., K. Arasteh, and M.L. Stitzer, “Comparative Effects of Alcohol and Marijuana on Mood, Memory, and Performance,” Pharmacology Biochemistry and Behavior, Vol. 58, 1997, pp. 93–101. Henningfield, J.E. and P.P. Woodson, “Dose-related Action of Nicotine on Behavior and Physiology: Review and Implica- tions for Replacement Therapy for Nicotine Dependence,” Journal of Substance Abuse, Vol. 1, 1989, pp. 301–317. Henningfield, J.E., A. Radzius, T.M. Cooper, and R.R. Clay- ton, “Drinking Coffee and Carbonated Beverages Blocks Absorption of Nicotine from Nicotine Polacrilex Gum,” Journal of the American Medical Association, Vol. 264, No. 12, 1990, pp. 1560–1564. Hider, J., “Viagra Renders Fighter Pilots a Potent Force,” The Times of London, Feb. 8, 2008. Hindmarch, I., “A Naturalistic Investigation of the Effect of Day-long Consumption of Tea, Coffee and Water on Alertness, Sleep Onset and Sleep Quality,” Psychopharma- cology, Vol. 149, 2000, pp. 203–216. Hindmarch, I. and Z. Shamsi, “Antihistamines: Models to Assess Sedative Properties, Assessment of Sedation, Safety and Other Side-effects,” Clinical Experimental Allergy, Vol. 29 (Supplement 3), 1999, pp. 133–142. Hindmarch, I., Z. Shamsi, and S. Kimber, “An Evaluation of the Effects of High-dose Fexofenadine on the Central Nervous System: A Double-blind, Placebo-controlled Study in Healthy Volunteers,” Clinical Experimental Allergy, Vol. 32, 2002, pp. 133–139. Hogervorst, E., W.J. Riedel, E. Kovacs, and J. Joiles, “Caffeine Improves Cognitive Performance after Strenuous Physi- cal Exercise,” International Journal of Sports Medicine, Vol. 20, 1999, pp. 354–361. Holloway, F.A., Low-dose Alcohol Effects on Human Behavior and Performance: A Review of post-1984 Research, FAA Technical Report No. DOT/FAA/AM-94-24, Civil Aero- medical Institute, Oklahoma City, Okla., 1994. Holmgren, A., P. Holmgren, F.C. Kugelberg, A.W. Jones, and J. Ahlner, “Predominance of Illicit Drugs and Poly-drug Use Among Drug-impaired Drivers in Sweden,” Traffic Injury Prevention, Vol. 8, No. 4, 2007, pp. 361–367. Horne, J.A. and L.A. Reyner, “Counteracting Driver Sleepi- ness: Effects of Napping, Caffeine, and Placebo,” Psycho- physiology, Vol. 33, 1996, pp. 306–309. Horne, J.A. and L.A. Reyner, “Beneficial Effects of an ‘Energy Drink’ Given to Sleepy Drivers,” Amino Acids, Vol. 20, No. 1, 2001, pp. 83–89. Houghton, P.J., “The Scientific Basis for the Reputed Activity of Valerian,” Journal of Pharmacy and Pharmacology, Vol. 51, 1999, pp. 505–512. Howard, M.E., et al., “Sleepiness, Sleep-disordered Breathing and Accident Risk Factors in Commercial Vehicle Drivers,” American Journal of Respiratory Critical Care Medicine, Vol. 170, 2004, pp. 1014–1021. Howarth, P.H., M.A. Stern, L. Roi, R. Reynolds, and J. Bousquet, “Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Fexofenadine Hydrochloride (120 and 180mg once daily) and Cetirizine

in Seasonal Allergic Rhinitis,” Journal of Allergy Clinical Immunology, Vol. 104, 1999, pp. 927–933. Hughes, J.R., “Distinguishing Withdrawal Relief and Direct Effects of Smoking,” Psychopharmacology (Berl), Vol. 104, 1991, pp. 409–410. Hughes, R.J. and P. Badia, “Sleep-promoting and Hypothermic Effects of Daytime Melatonin Administration in Humans,” Sleep, Vol. 20, 1997, pp. 124–131. Hurst, M. and S. Noble, “Zaleplon,” CNS Drugs, Vol. 11, No. 5, 1999, pp. 387–392. Institute of Medicine (IOM), Halcion: An Independent Assessment of Safety and Efficacy Data, Division of Health Sciences Policy, IOM, National Academy of Sciences, Washington, D.C., 1997. Institute of Medicine (IOM), Dietary Supplements: A Frame- work for Evaluating Safety, IOM, National Academy of Sciences, Washington, D.C., 2005. Institute of Medicine (IOM), Use of Dietary Supplements by Military Personnel, Committee on the Use of Dietary Supplements by Military Personnel—Food and Nutrition Board, National Academy of Sciences, IOM, Washington, D.C., 2008. Institute of Medicine—Committee on Military Nutrition Research (IOM-CMNR), Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Oper- ations, National Academy Press, Washington, D.C., 2001. Institute of Medicine—Committee on Military Nutrition Research (IOM-CMNR), Nutrient Composition of Rations for Short-term, High-intensity Combat Operations, National Academy Press, Washington, D.C., 2005. International Council on Alcohol, Drugs and Traffic Safety (ICADTS), “Prescribing and Dispensing Guidelines for Medicinal Drugs Affecting Driving Performance,” ICADTS, Oosterhuut, the Netherlands, 2001. International Council on Alcohol, Drugs and Traffic Safety (ICADTS), “Categorization System for Medicinal Drugs Affecting Driving Performance,” ICADTS, Ann Arbor, Mich., 2006 [Online]. Available: http://www.icadts.org/ reports/medicinaldrugs1.pdf. Isawa, S., M. Suzuki, M. Uchiumi, and M. Murasaki, “The Effect of Zolpidem and Zopiclone on Memory and Psycho- motor Performance,” Nihon Shinkei Seishin Yakurigaku Zasshi, Vol. 20, No. 2, 2000, pp. 61–69. Izzo, A.A. and E. Ernst, “Interactions Between Herbal Medicines and Prescribed Drugs: A Systematic Review,” Drugs, Vol. 61, 2001, pp. 2163–2175. James, J.E., “Does Caffeine Enhance or Merely Restore Degraded Psychomotor Performance?” Neuropsychobiol- ogy, Vol. 30, 1994, pp. 124–125. James, J.E., “Caffeine and Psychomotor Performance Revis- ited,” Neuropsychobiology, Vol. 31, 1995, pp. 202–203. James, J.E., “Acute and Chronic Effects of Caffeine on Perfor- mance, Mood, Headache, and Sleep,” Neuropsychobiology, Vol. 38, 1998, pp. 32–41. Jarvik, M.E. and J.E. Henningfield, “Pharmacologic Treatment of Tobacco Dependence,” Pharmacological and Bio- chemical Behavior, Vol. 30, 1988, pp. 279–294. 100 Jarvis, M.J., “Does Caffeine Intake Enhance Levels of Cognitive Performance?” Psychopharmacology, Vol. 110, 1993, pp. 45–42. Jay, S.M., R.M. Petrilli, S.A. Ferguson, D. Dawson, and N. Lamond, “The Suitability of a Caffeinated Energy Drink for Night-shift Workers,” Physiology and Behavior, Vol. 87, No. 5, 2006, pp. 925–931. Johnson, E.O., T. Roehers, T. Roth, and N. Breslau, “Epidemiology of Alcohol and Medication as Aids to Sleep in Early Adulthood,” Sleep, Vol. 21, 1998, pp. 178–186. Johnson, L.C. and D.A. Chernik, “Sedative-hypnotics and Human Performance,” Psychopharmacology, Vol. 76, 1982, pp. 101–113. Johnson, M.W., P.E. Suess, and R.R. Griffiths, “Ramelteon: A Novel Hypnotic Lacking Abuse Liability and Sedative Adverse Effects,” Archives of General Psychiatry, Vol. 63, 2006, pp. 1149–1157. Johnson, R.D. and R.J. Lewis, Identification of Sildenafil (Viagra®) and Its Metabolite (UK-103,320) in Six Aviation Fatalities, CAMI Technical Report No. DOT-FAA-AM- 06-3, Federal Aviation Administration Civil Aerospace Medical Institute, Oklahoma City, Okla., 2006. Johnson, R.D., R.J. Lewis, and M.K. Angier, The LC/MS Quantitation of Vardenafil (Levitra®) in Postmortem Bio- logical Specimens, CAMI Technical Report No. DOT- FAA-AM-06-17, Federal Aviation Administration Civil Aerospace Medical Institute, Oklahoma City, Okla., 2006. Jones, A.W., “Driving Under the Influence of Drugs in Sweden,” Human Experimental Toxicology, Vol. 24, 2005, pp. 615–622. Jones, R.K., D. Shinar, and J.M. Walsh, State of Knowledge of Drug Impaired Driving, NHTSA Technical Report DOT HS 809-642, National Highway Transportation Safety Administration, Washington, D.C., 2003. Jufe, G.S., “New Hypnotics: Perspectives from Sleep Physi- ology,” Vertex, Vol. 18, No. 74, 2007, pp. 294–299. Kalmar, J.M. and E. Cafarelli, “Caffeine: A Valuable Tool to Study Central Fatigue in Humans?” Exercise Sport Science Review, Vol. 32, No. 4, 2004, pp. 143–147. Kamaldeep, D., K. Suresh, and S. Anupam, “Anti-anxiety Studies on Extracts of Passiflora Incarnata Linneaus,” Journal of Ethnopharmacology, Vol. 78, 2001, pp. 165–170. Kamaldeep, D., D. Sanju, and S. Anupam, “Passiflora: Reviews Update,” Journal of Ethnopharmacology, Vol. 94, 2004, pp. 1–23. Kamimori, G.H., “Effect of Three Caffeine Doses on Plasma Catecholamines and Alertness During Prolonged Wake- fulness,” European Journal of Clinical Pharmacology, Vol. 56, 2000, pp. 537–544. Kamimori, G.H., et al., “The Rate of Absorption and Relative Bioavailability of Caffeine Administered in Chewing Gum Versus Capsules to Normal Healthy Volunteers,” International Journal of Pharmaceutics, Vol. 234, 2002, pp. 159–167. Kay, G.G., “The Effects of Antihistamines on Cognition and Performance,” Journal of Allergy and Clinical Immunology, Vol. 105, No. 6 (Supplement), 2000, pp. S622–S627.

101 Kay, G.G. and A.G. Harris, “Loratadine: A Non-sedating Antihistamine: Review of Its Effects on Cognition, Psychomotor Performance, Mood and Sedation,” Clinical and Experimental Allergy, Vol. 29 (Supplement 3), 1999, pp. 147–150. Kay, G.G. and M.E. Quig, “Impact of Sedating Antihistamines on Safety and Productivity,” Allergy and Asthma Pro- ceedings, Vol. 22, No. 5, 2001, pp. 281–283. Kay, G.G., et al., “Initial and Steady-state Effects of Diphen- hydramine and Loratadine on Sedation, Cognition, Mood and Psychomotor Performance,” Archives of Internal Medicine, Vol. 157, 1997, pp. 2350–2356. Kay, G.G., K.E. Plotkin, M.B. Quig, V.N. Starbuck, and S. Yasuda, “Sedating Effects of AM/PM Antihistamine Dosing with Evening Chlorpheniramine and Morning Terfenadine,” American Journal of Managed Care, Vol. 3, 1997a, pp. 1843–1848. Kay, G.G., et al., “Initial and Steady-state Effects of Diphen- hydramine and Loratadine on Sedation, Cognition, Mood, and Psychomotor Performance,” Archives of Internal Medicine, Vol. 57, 1997, pp. 2350–2356. Kay, G.G., M.A. Michaels, and B. Pakull, “Simulated Driving Changes in Young Adults with ADHD Receiving Mixed Amphetamine Salts Extended Release and Atomoxetine,” Journal of Attention Disorders, Vol. 12, No. 4, 2009, pp. 316–329. Kelly, E., S. Drake, and J. Ross, “A Review of Drug Use and Driving: Epidemiology, Impairment, Risk Factors and Risk Perceptions,” Drug and Alcohol Review, Vol. 23, No. 3, 2004, pp. 319–344. Kelly, T.L., et al., Effects of Repeated Doses of Caffeine During 64 Hours of Sleep Deprivation on Subsequent Recovery Sleep, NHRC Technical Report No. 96-11, U.S. Naval Health Research Center, San Diego, Calif., 1996. Kenagy, D.N., C. Bird, C.M. Webber, and J.R. Fischer, “Dextroamphetamine Used During B-2 Combat Missions,” Aviation, Space and Environmental Medicine, Vol. 75, No. 5, 2004, pp. 381–386. Kennedy, D.O. and A.B. Scholey, “Ginseng: Potential for the Enhancement of Cognitive Performance and Mood,” Pharmacology Biochemistry and Behavior, Vol. 75, No. 3, 2003, pp. 687–700. Kennedy, D.O. and A.B. Scholey, “A Glucose-caffeine ‘Energy Drink’ Ameliorates Subjective and Performance Deficits During Prolonged Cognitive Demand,” Appetite, Vol. 42, No. 3, 2004, pp. 331–333. Kennedy, D.O., A.B. Scholey, and K.A. Wesnes, “The Dose- dependent Cognitive Effects of Acute Administration of Ginkgo Biloba to Healthy Young Volunteers,” Psycho- pharmacology, Vol. 151, 2000, pp. 416–423. Kennedy, D.O., A.B. Scholey, and K.A. Wesnes, “Differential, Dose Dependent Changes in Cognitive Performance Follow- ing Acute Administration of a Ginkgo Biloba/Panax Ginseng Combination to Healthy Young Volunteers,” Nutrition and Neuroscience, Vol. 4, No. 5, 2001, pp. 399–412. Kennedy, D.O., A.B. Scholey, and K.A. Wesnes, “Modulation of Cognition and Mood Following Administration of Single Doses of Ginko Biloba, Ginseng, and a Ginkgo/Ginseng Combination to Healthy Young Adults,” Physiological Behavior, Vol. 75, No. 5, 2002, pp. 739–751. Kennedy, D.O., C.F. Haskell, K.A. Wesnes, and A.B. Scholey, “Improved Cognitive Performance in Human Volunteers Following Administration of Guarana (Paullinia cupana) Extract: Comparison and Interaction with Panax Ginseng,” Pharmacology Biochemistry and Behavior, Vol. 79, No. 3, 2004, pp. 401–411. Kennedy, D.O., P.A. Jackson, C.F. Haskell, and A.B. Scholey, “Modulation of Cognitive Performance Following Single Doses of 120mg Ginkgo Biloba Extract Administered to Healthy Young Volunteers,” Human Psychopharmacology, Vol. 22, No. 8, 2007, pp. 559–566. Kennedy, D.O., et al., “Improved Cognitive Performance and Mental Fatigue Following a Multi-vitamin and Mineral Supplement with Added Guarana (Paullinia Cupana),” Appetite, Vol. 50, No. 2–3, 2008, ePub October 2007, pp. 506–513. Kilham, C.S., “Kava, Medicine Hunting in Paradise: The Pursuit of a Natural Alternative to Anti-anxiety Drugs and Sleeping Pills,” Park Street Press, Rochester, Vt., 1996. Kilham, C., Kava: Medicine Hunting in Paradise, Park Street Press, New York, N.Y., 1996. Killgore, W.D.S., E.E. Kahn-Greene, N.L. Grugle, D.B. Kill- gore, and T.J. Balkin, “Sustaining Executive Functions During Sleep Deprivation: A Comparison of Caffeine, Dextroamphetamine, and Modafinil,” Sleep, Vol. 32, No. 2, 2009, pp. 205–216. Kim, W., “Debunking the Effects of Taurine in Red Bull Energy Drink,” Nutrition Bytes, Vol. 9, No. 1, article 6, Department of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, 2003 [Online]. Available: http://repositories.cdlib.org/ uclabiolchem/nutrition bytes/vol9/iss1/art6. Kleijnen, J. and P. Knipschild, “Ginkgo Biloba,” Lancet, Vol. 340, No. 8828, 1992, pp. 1136–1139. Kloner, R.A. and R.M. Zusman, “Cardiovascular Effects of Sildenafil Citrate and Recommendations for Its Use,” Amer- ican Journal of Cardiology, Vol. 84, 1999, pp. 11N–17N. Knipling, R.R., Ed., Transportation Research Circular No. E-C117: The Domain of Truck and Bus Safety Research, Transportation Research Board of the National Academies, Washington, D.C., May 2007. Kobler, M., G.R. Spooner, and O. Szafran, “Adverse Events with Zyban (Buproprion),” Canadian Medical Association Journal, Vol. 169, No. 2, 2003, pp. 103–104. Koelega, H.S., “Stimulant Drugs and Vigilance Performance: A Review,” Psychopharmacology, Vol. 111, 1991, No. 1, pp. 1–16. Krueger, G.P., “Sustained Work, Fatigue, Sleep Loss and Performance: A Review of the Issues,” Work and Stress, Vol. 3, No. 2, 1989, pp. 129–141. Krueger, G.P., “Environmental Medicine Research to Sustain Health and Performance During Military Deployment: Desert, Arctic, High Altitude Stressors,” Journal of Thermal Biology, Vol. 18, No. 5/6, 1993, pp. 687–690.

Krueger, G.P., Truck Driver Hours of Service Considerations, A Literature Review: Rest and Recovery, Split Sleep Schedules, Extended Periods of Driving, and Time Off Between Duty Shifts, Technical Report for American Truck- ing Associations’ Foundation Trucking Research Institute, Star Mountain, Inc., Alexandria, Va., June 1997. Krueger, G.P., “Mastering Alertness and Managing Commer- cial Driver Fatigue: Commercial Driver Fatigue Outreach Training Program,” In: Proceedings of Truck Driver Occu- pational Safety and Health Conference, M.H. Belzer and G.M. Saltzman, Eds., Sponsored by U.S.DOT’s Federal Motor Carrier Safety Administration (FMCSA) and Ameri- can Trucking Associations (ATA), Apr. 24–25, 2003, Wayne State University, Detroit, Mich., pp. 61–71, 131–132. Krueger, G.P., “Psychoactive Medications, Stimulants, Hyp- notics, and Nutritional Aids: Effects on Driving Alertness and Performance,” Journal of the Washington Academy of Sciences, Vol. 96, No. 4, 2010, pp. 51–85. Krueger, G.P. and H. Babkoff, “Stimulants to Ameliorate Sleep Loss During Sustained Operations,” Military Psy- chology (special issue), Vol. 4, No. 4, 1992, pp. 189–287. Krueger, G.P. and R.M. Brewster, Gettin’-in-Gear: Wellness, Health, and Fitness Program for Commercial Drivers: Instructors Manual, American Trucking Associations’ American Transportation Research Institute in partnership with the Federal Motor Carrier Safety Administration, Alexandria, Va., 2002. Krueger, G.P. and R.M. Brewster, “Commercial Driver Well- ness, Health and Fitness: A Program for Mastering Driver Alertness and Managing Fatigue,” In: Proceedings of the International Conference on Fatigue Management in Trans- portation, Seattle, Wash., Sep. 2005. Krueger, G.P. and S.B. Van Hemel, Effects of Loading and Unloading Cargo on Commercial Truck Driver Alertness and Performance, Federal Motor Carrier Safety Administra- tion Technical Report No. DOT-MC-01-107, U.S. Depart- ment of Transportation, Washington, D.C., May 2001. Krueger, G.P. and H.M. Leaman, Stimulants, Hypnotics, Nutritional Aids, Medications and Other Chemical Substances: Their Effects on Driving Alertness and Per- formance, presentation Mar. 25, 2009, the International Conference on Fatigue Management in Transportation Operations: A Framework for Progress. Krueger, G.P., et al., “Health and Wellness of Commercial Drivers,” In: Transportation Research Circular No. E-C117: The Domain of Truck and Bus Safety Research, Chapter 4, R.R. Knipling, Ed., Truck and Bus Safety Committee, Transportation Research Board of the National Academies, Washington, D.C., May 2007a, pp. 58–91. Krueger, G.P., R.M. Brewster, V.R. Dick, R. Inderbitzen, and L. Staplin, CTBSSP Synthesis of Commercial Truck and Bus Safety 15: Health and Wellness Programs for Commercial Drivers, Transportation Research Board of the National Academies, Washington, D.C., May 2007b [Online]. Available: http://www.trb.org/news/blurb_detail. asp?id=7920. Krystal, A.D., “The Treatment of Primary Insomnia,” CNS Spectr, Vol. 12, Supplement 13, Dec. 2009, pp. 6–10. 102 Kunsman, G.W., J.E. Manno, B.R. Manno, C.M. Kunsman, and M.A Przekop, “The Use of Microcomputer-based Psychomotor Tests for the Evaluation of Benzodiazepine Effects on Human Performance: A Review with Emphasis on Temazepam,” British Journal of Clinical Pharmacology, Vol. 34, No. 4, 1992, pp. 289–391. Kurtzweil, P., A FDA Guide to Dietary Supplements, Center for Food Safety and Applied Nutrition’s Dietary Supplements, FDA Consumer, U.S. Food and Drug Administration, Washington, D.C., 1999 [Online]. Available: http://www. cfsan.fda.gov/∼dms/fdsupp.html. Lagarde, D. and D. Batejat, “Disrupted Sleep-wake Rhythm and Performance: Advantages of Modafinil,” Military Psychology, Vol. 7, 1995, pp. 165–191. Laberge, J.C. and N.J. Ward, “Research Note—Cannabis and Driving: Research Needs and Issues for Transportation Policy,” Journal of Drug Issues, Fall 2004, pp. 971–989. Lagarde, D., D. Batejat, P. Van Beers, D. Sarafian, and S. Pradella, “Interest of Modafinil, A New Psychostimu- lant, During a Sixty-hour Sleep Deprivation Experiment,” Fundamentals of Clinical Pharmacology, Vol. 9, 1995, pp. 271–279. Landstrom, U., A. Knutsson, M. Lennenas, and L. Söderberg, “Laboratory Studies of the Effects of Carbohydrate Con- sumption on Wakefulness,” Nutrition and Health, Vol. 13, 2000, pp. 213–225. Langtry, H.D. and P. Benfield, “Zolpidem: A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential,” Drugs, Vol. 40, 1990, pp. 291–313. Lankford, A. and S. Ancoli-Israel, “Indiplon: The Develop- ment of a Novel Therapy for the Treatment of Sleep Onset and Sleep Maintenance Insomnia,” International Journal of Clinical Practice, Vol. 61, No. 6, 2007, pp. 1037–1045. Laumon, B., B. Grdegbeku, J.-L. Martin, and M.-B. Blecheler, “Cannabis Intoxication and Fatal Road Crashes in France: Population Based Case-control Study,” British Medical Journal, Vol. 331, 2005, pp. 1371–1374. Leathwood, P.D., R. Chauffard, E. Heck, and R. Munoz-Box, “Aqueous Extract of Valerian Root (Valeriana Officinalis L.) Improves Sleep Quality in Man,” Pharmacological Bio- chemistry and Behavior, Vol. 17, 1982, pp. 65–71. Lebot, V., L. Lindstrom, and M. Merlin, “Kava, the Pacific Drug,” In: Psychoactive Plants of the World Series, Yale University Press, New Haven, Conn., 1992. Leese, P., G. Maier, L. Vaickus, and E. Akylbekova, “Esopi- clone: Pharmacokinetic and Pharmacodynamic Effects of a Novel Sedative Hypnotic After Daytime Administration in Healthy Subjects” [abstr.], Sleep, 2002, supplement A45. LeHouezec, J., R. Halliday, N.L. Benowitz, E. Callaway, H. Naylor, and K. Herzig, “A Low Dose of Subcutaneous Nicotine Improves Information Processing in Non-smokers,” Psychopharmacology, Vol. 114, 1994, pp. 628–634. Lemont, V., M. Merlin, and L. Lindstrom, Kava, the Pacific Elixir: The Definitive Guide to Its Ethnobotany, History, and Chemistry, Healing Arts Press, Rochester, Vt., 1997. Lettieri, C.J., T.N. Quast, A.H. Eliasson, and T. Andrada, “Eszopiclone Improves Overnight Polysomnography and

103 Continuous Positive Airway Pressure Titration: A Prospec- tive, Randomized, Placebo-controlled Trial,” Sleep, Vol. 31, No. 9, 2008, pp. 1310–1316. Leung, A.Y. and S. Foster, Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics, 2nd ed., John Wiley and Sons, New York, N.Y., 1996. Lieberman, H.R., “Cognitive Effects of Various Food Constituents,” In: Handbook of the Psychophysiology of Human Eating, R. Shepard, Ed., Wiley and Sons, Ltd., Chicester, U.K., 1989, pp. 251–270. Lieberman, H.R., “Tyrosine and Stress: Human and Animal Studies,” In: Food Components to Enhance Performance, B. Marriot, Ed., National Academy Press, Washington, D.C., 1994, pp. 277–299. Lieberman, H.R., “The Effects of Ginseng, Ephedrine and Caffeine on Cognitive Performance, Mood and Energy,” Nutrition Reviews, Vol. 59, No. 4, 2001, pp. 91–102. Lieberman, H.R. and M.Z. Mays, “Scenarios That Illustrate Potential Usefulness of Food Components to Enhance Per- formance, Appendix A,” In: Food Components to Enhance Performance: An Evaluation of Potential Performance- Enhancing Food Components for Operational Rations, B.M. Marriot, Ed., Committee on Military Food and Nutri- tion Research, Institute of Medicine, National Academy of Sciences, Washington, D.C., 1994. Lieberman, H.R., F. Waldhauser, and R.J. Wurtman, “Effects of Melatonin on Human Mood and Performance,” Brain Research, Vol. 323, 1984, pp. 201–210. Lieberman, H.R., et al., “The Effects of Low Doses of Caffeine on Human Performance and Mood,” Psychopharmacology, Vol. 92, 1987, pp. 308–312. Lieberman, J.A., “Update on the Safety Considerations in the Management of Insomnia with Hypnotics: Incorporating Modified-release Formulations into Primary Care. Primary Care Companion,” Journal of Clinical Psychiatry, Vol. 9, 2007, pp. 25–31. Lindahl, O. and L. Landwall, “Double Blind Study of a Valerian Preparation,” Pharmacological Biochemistry and Behavior, Vol. 32, 1989, pp. 1065–1066. Lockey, R.F., et al., “Comparative Study of Cetirizine and Terfenadine Versus Placebo in the Symptomatic Manage- ment of Seasonal Allergic Rhinitis,” Annals of Allergy Asthma Immunology, Vol. 76, 1996, pp. 448–454. Logan, B.K., “Methamphetamine and Driving Impairment,” Journal of Forensic Science, Vol. 41, 1996, pp. 457–464. Logan, B.K., “Methamphetamine: Effects on Human Perfor- mance and Behavior,” Forensic Science Review, Vol. 14, 2002, pp. 133–151. Longo, M.C., C.E. Hunger, R.J. Lokan, J.M. White, and M.A. White, “The Prevalence of Alcohol, Cannabinoids, Benzodiazepines and Stimulants Amongst Injured Drivers and Their Role in Driving Culpability, Part I: The Preva- lence of Drug Use in Drivers, and Characteristics of the Drug-positive Group,” Accident Analysis and Prevention, Vol. 32, No. 5, 2000a, pp. 613–622. Longo, M.C., C.E. Hunger, R.J. Lokan, J.M. White, and M.A. White, “The Prevalence of Alcohol, Cannabinoids, Benzodiazepines and Stimulants Amongst Injured Drivers and Their Role in Driving Culpability, Part II: The Relation- ship Between Drug Prevalence and Drug Concentration, and Driver Culpability,” Accident Analysis and Prevention, Vol. 32, No. 5, 2000b, pp. 623–632. Lyvers, M., I. Matlzman, and Y. Miyata, “Effects of Cigarette Smoking and Smoking Deprivation on Wisconsin Card Sorting Test Performance,” Experimental Clinical Psycho- pharmacology, Vol. 2, 1994, pp. 283–289. Magill, R.A., et al., “Effects of Tyrosine, Phentermine, Caffeine, D-amphetamine, and Placebo on Cognitive and Motor Performance Deficits During Sleep Deprivation,” Nutritional Neuroscience, Vol. 6, No. 4, 2003, pp. 237–246. Malinauskas, B.M., V.G. Aeby, R.F. Overton, T. Carpenter- Aeby, and K. Barber-Heidal, “A Survey of Energy Drink Consumption Patterns Among College Students,” Nutrition Journal, Vol. 6, No. 35, 2007, 7 pp. Mamelak, M., “Gammahydroxybutyrate: An Endogenous Regulator of Energy Metabolism,” Neuroscience and Biobehavioral Review, Vol. 13, No. 4, 1989, pp. 187–198. Manning, C.A., J.L. Hall, and P.E. Gold, “Glucose Effects on Memory and Other Neuropsychological Tests in Elderly Humans,” Psychological Science, 1990, Vol. 1, pp. 307–311. Marrs, J.C., “Indiplon: A Nonbenzodiazepine Sedative- hypnotic for the Treatment of Insomnia,” Annals of Pharmacotherapy, Vol. 42, No. 7, 2008, pp. 1070–1079. Mayer, S., “The Influence of a Taurine Containing Drink on Cardiac Parameters and Physical Performance: Results of Four Studies,” Journal of Science and Medicine in Sport, Vol. 5, No. 4, Supplement 1, 2002, p. 57 [Poster at Australian Conference of Science and Medicine in Sport 2002]. McArdle, W.D., F.I. Katch, and V.L. Katch, Exercise Physiology: Energy, Nutrition and Human Performance, 3rd ed., Lea and Febiger, Malvern, Pa., 1991. McBay, A.J., “Drug Concentrations and Driving Impairment: Consensus Report—Letter to the Editor,” Journal of Forensic Science, Vol. 34, 1989, pp. 3–4. McBay, A.J., “Drugs and Driving Impairment,” University of North Carolina, Chapel Hill, N.C., Extracted from the Web at Schaffer Library of Drug Policy, 1997 [Online]. Available: http://www.druglibrary.org/schaffer/MISC/ driving/ddimp.htm. McClellan, K.J. and C.M. Spencer, “Modafinil: A Review of its Pharmacology and Clinical Efficacy in the Manage- ment of Narcolepsy,” CNS Drugs, Vol. 9, No. 4, 1998, 311–324. McGehee, D.S., “Nicotinic and Opiod Receptor Interactions in Nicotine Addiction,” Molecular Interventions, Vol. 6, 2006, pp. 311–314. McLellan, T.M., D.G. Bell, H.R. Lieberman, and G.H. Kamimori, “The Impact of Caffeine on Cognitive and Physical Performance and Marksmanship During Sustained Operations,” Canadian Military Journal: Military Medicine, Vol. 4, 2003–2004, pp. 47–54. McLellan, T.M., G.H. Kamimori, D.G. Bell, I.F. Smith, D. Johnson, and G. Belenky, “Caffeine Maintains Vigilance

and Marksmanship in Simulated Urban Operations with Sleep Deprivation,” Aviation, Space, and Environmental Medicine, Vol. 76, No. 1, 2005a, pp. 39–45. McLellan, T.M., G.H. Kamimori, D.M. Voss, D.G. Bell, K.G. Cole, and D. Johnson, “Caffeine Maintains Vigilance and Improves Run Times During Night Operations for Special Forces,” Aviation, Space and Environmental Medicine, Vol. 76, 2005b, pp. 647–654. Meltzer, E.O., J.M. Weiler, and M.D. Widlitz, “Comparative Outdoor Study of the Efficacy, Onset and Duration of Action, and Safety of Cetirizine, Loratadine, and Placebo for Seasonal Allergic Rhinitis,” Journal of Allergy and Clinical Immunology, Vol. 97, 1996, pp. 617–626. Mendelson, W.B., Human Sleep: Research and Clinical Care, Plenum Press, New York, N.Y., 1987. Mendelson, W.B., “Hypnotic Medications: Mechanisms of Action and Pharmacologic Effects,” In: Principles and Practice of Sleep Medicine, 4th ed., Chapter 36, M.H. Kryger, T. Roth, and W.C. Dement, Eds., Elsevier Saun- ders, Philadelphia, Pa., 2005, pp. 444–451. Metzner, J., et al., “Psychiatric Disorders and Commercial Motor Vehicle Driver Safety, Opinions of Expert Panel,” Federal Motor Carrier Safety Administration, U.S. Department of Transportation, Washington, D.C., Aug. 13, 2009 [Online]. Available: http://www.fmcsa.dot.gov/rules- regulations/TOPICS/mep/report/Medical-Expert-Panel- Psychiatric-Psychiatric-MEP-Panel-Opin.pdf [accessed Mar. 3, 2010]. Milgram, N.W., H. Callahan, and C. Siwak, “Adrafinil: A Novel Vigilance Promoting Agent,” CNS Drug Reviews, Vol. 5, No. 3, 1999, pp. 193–212. Miller, L.G., et al., “White Paper on Herbal Products,” American College of Clinical Pharmacy’s Journal of Pharmacotherapy, Vol. 20, 2000, pp. 877–891. Mintzer, M.Z., J. Guarino, T. Kirk, J.D. Roache, and R.R. Griffiths, “Ethanol and Pentobarbital: Comparison of Behav- ioral and Subjective Effects in Sedative Drug Abusers,” Experimental and Clinical Psychopharmacology, Vol. 5, No. 3, 1997, pp. 203–215. Mitler, M.M. and M.S. Aldrich, “Stimulants Efficacy and Adverse Effects,” In: Principles and Practice of Sleep Medicine, 3rd ed., M.H. Kryger, T. Roth, and W.C. Cement, Eds., W.B. Saunders Co., Philadelphia, Pa., 2000, pp. 429–440. Mitler, M.M. and M.B. O’Malley, “Wake-promoting Med- ications: Efficacy and Adverse Effects,” In: Principles and Practice of Sleep Medicine, 4th ed., Chapter 39, M.H. Kryger, T. Roth, and W.C. Dement, Eds., Elsevier Saunders, Philadelphia, Pa., 2005, pp. 484–498. Mitler, M.M., F. Shafor, R. Hajdukovic, R.M. Timms, and C.P. Browman, “Treatment of Narcolepsy: Objective Studies on Methylphenidate, Pemoline, and Protriptyline,” Sleep, Vol. 9, 1986, pp. 260–264. Moja, E.A., E. Antinoro, M. Cesa-Bianchi, and G.L. Gessa, “Increase in Stage 4 Sleep After Ingestion of a Tryptophan- free Diet in Humans,” Pharmacological Research Com- munications, Vol. 16, 1984, pp. 909–914. 104 Moolenar, M., P.A. Desmond, D. Mascord, G. Starmer, and B. Tattam, “The Effects of Ephedrine on the Development of Fatigue in a Prolonged Driving-related Task,” Human Psychopharmacology: Clinical and Experimental, Vol. 14, 1999, pp. 415–427. Moore, E.C., “Zaleplon (Sonata®, Wyeth Ayerst): A New, Non-benzodiazepine Sedative/hypnotic,” Journal of the Pharmacy Society of Wisconsin, Sep./Oct. 2000, pp. 33–38. Moskowitz, H., “Alcohol and Drugs,” In: Human Factors in Traffic Safety, R.E. Dewar and P. Olson, Eds., Lawyers and Judges Publishing, Tucson, Ariz., 2002, pp. 177–207. Moskowitz, H., “Alcohol and Drugs,” Chapter 7, In: Human Factors in Traffic Safety, 2nd ed., Lawyers and Judges Publishing, Tucson, Ariz., 2007, pp. 123–142. Moskowitz, H. and C.D. Robinson, Effects of Low Doses of Alcohol on Driving-related Skills: A Review of the Evidence, NHTSA Technical Report No. DOT HS 807-280, National Highway Transportation Safety Administration, U.S. Department of Transportation, Washington, D.C., 1988. Moskowitz, H. and M. Burns, “The Effects of a Single, Acute Dose of Cocaine upon Driving-related Skills Performance,” In: Proceedings of the 11th International Conference on Alcohol, Drugs and Traffic Safety (T-89), Verlag TUV Rheinland, Cologen, Germany, 1989. Moskowitz, H. and M. Burns, “Effects of Terfenadine, Diphenhydramine, and Placebo on Skills Performance,” Cutis, Vol. 42, No. 4A, 1998, pp. 14–18. Moskowitz, H. and D. Fiorentino, A Review of the Literature on the Effects of Low Doses of Alcohol on Driving-related Skills, NHTSA Technical Report No. DOT HS 809-028, National Highway Transportation Safety Administration, U.S. Department of Transportation, Washington, D.C., 2000. Mumenthaler, M.S., J.L. Taylor, R. O’Hara, and J.A. Yesavage, “Influence of Nicotine on Simulator Flight Performance in Non-smokers,” Psychopharmacology, Vol. 140, 1998, pp. 38–41. Mumenthaler, M.S., et al., “Psychoactive Drugs and Pilot Performance: A Comparison of Nicotine, Donepezil, and Alcohol Effects,” Neuropsychopharmacology, Vol. 28, 2003, pp. 1366–1373. Mumenthaler, M.S., N.L. Benowitz, J.L. Taylor, L. Friedman, A. Noda, and J.A. Yesavage, “Nicotine Deprivation and Pilot Performance During Simulated Flight, “Aviation, Space and Environmental Medicine,” Vol. 81, 2010, pp. 660–664. National Highway Traffic Safety Administration (NHTSA), “Marijuana and Actual Driving Performance,” DOT Tech- nical Report No. HS 808 078, Final Report, U.S. Depart- ment of Transportation, Washington, D.C., Nov. 1993. National Highway Traffic Safety Administration, Medical Conditions and Driving: A Review of the Literature, 1960–2000; Section 13, Drugs, NHTSA Report DOT-HS- 809-690, National Highway Traffic Safety Administration (NHTSA), U.S. Department of Transportation, Washington, D.C., 2005.

105 National Institute on Drug Abuse, “Commonly Abused Drugs Chart,” U.S. National Institute of Drug Abuse, Rockville, Md., 2006 [Online]. Available: http://www.nida.nih.gov/ drugpages/drugsofabuse.html. National Institute on Drug Abuse (NIDA), NIDA InfoFacts: Prescription Pain and Other Medications, NIDA, National Institutes of Health, Department of Health and Human Services, Bethesda, Md., June 2006 [Online]. Available: http://www.drugabuse.gov/infofacts/PainMed.html. National Institute for Occupational Health and Safety, “National Occupational Research Agenda (NORA), Trans- portation, Warehousing and Utilities (TWU) Agenda: For Occupational Safety and Health Research and Practice in the U.S. TWU Occupational Sector. Goals and Objectives of the Transportation Sector,” 2010 [Online]. Available: http://www.cdc.gov/niosh/nora/. National Sleep Foundation, 1998 Omnibus Sleep in America Poll, Washington, D.C., 1998. National Sleep Foundation, National Sleep Foundation’s Sleep, Health and Safety Conference, Public Health and Safety Track, Prince Georges County, Md., Mar. 5–6, 2010 [Online]. Available: www.sleepfoundation.org. National Transportation Safety Board, Safety Study: Fatigue, Alcohol, Other Drugs and Medical Factors in Fatal- to-the-driver Heavy Truck Crashes (Volume 1), NTSB Technical Report No. SS-90-01, National Transportation Safety Board, Washington, D.C., 1990. National Transportation Safety Board, Factors That Affect Fatigue in Heavy Truck Accidents. Volume 1: Analysis; Volume 2: Case Summaries, National Transportation Safety Board, Washington, D.C., 1995. Naylor, H., R. Halliday, and E. Callaway, “The Effect of Methylphenidate on Information Processing,” Psycho- pharmacology, Vol. 86, 1985, pp. 90–95. Neri, D.F., D. Wiegmann, R.R. Stanny, S.A. Happell, A. McCardie, and D.L. McKay, “The Effects of Tyrosine on Cognitive Performance During Extended Wakefulness,” Aviation, Space, and Environmental Medicine, Vol. 66, No. 4, 1995, pp. 313–319. Neuhouser, M.L., et al. “Multivitamin Use and Risk of Cancer and Cardiovascular Disease in the Women’s Health Initiative Cohorts,” Archives of Internal Medicine, Vol. 169, No. 3, 2009, pp. 294–304. Newhouse, P.A., G. Belenky, M. Thomas, D. Thorne, H. Sing, and J. Fertig, “The Effects of d-amphetamine on Arousal, Cognition, and Mood After Prolonged Total Sleep Deprivation,” Neuropsychopharmacology, Vol. 2, 1989, pp. 153–164. Newhouse, P.A., et al., “Stimulant Drug Effects on Perfor- mance and Behavior After Prolonged Sleep Deprivation: A Comparison of Amphetamine, Nicotine, and Deprenyl,” Military Psychology, Vol. 4, 1992, pp. 207–233. Nicholson, A.N., “Long-range Air Capability and the South Atlantic Campaign,” Aviation, Space, and Environmental Medicine, Vol. 55, 1984, pp. 269–270. Nicholson, A.N., “Hypnotics and Occupational Medicine,” Journal of Occupational Medicine, Vol. 32, 1990, pp. 335–341. Nicholson, A.N., “Residual Sequelae of Zopiclone,” Review of Contemporary Pharmacotherapy, Vol. 9, 1998, pp. 123–129. Nicholson, A.N., “Fatigue Countermeasures and the Use of Hypnotics in Aircrew,” Letter to the Editor, Aviation, Space, and Environmental Medicine, Vol. 80, No. 4, 2009, p. 418. Nicholson, A.N. and P.A. Pascoe, “Hypnotic Activity of Zolpidem: Night-time and Daytime Studies in Young and Middle-aged Adults,” In: Imidazopyridines in Sleep Dis- orders, J.P. Sauvanet, S.Z. Langer, and P.L. Morselli, Eds., Raven Press, New York, N.Y., 1988, pp. 231–240. Nicholson, A.N. and C. Turner, “Central Effects of the H1-antihistamine, Cetirizine,” Aviation, Space and Envi- ronmental Medicine, Vol. 69, 1998, pp. 166–171. Nicholson, A.N. and C. Turner, “Intensive and Sustained Air Operations: Potential Use of the Stimulant Pemoline,” Aviation, Space, and Environmental Medicine, Vol. 69, No. 7, 1998, pp. 647–655. Nicholson, A.N., B.M. Stone, and P.A. Pascoe, “Efficacy of Some Benzodiazepines for Day-time Sleep,” British Journal of Clinical Pharmacology, Vol. 1980, pp. 459–463. Nicholson, A.N., T. Roth, and B. Stone, “Hypnotics and Aircrew,” Aviation, Space, and Environmental Medicine, Vol. 56, 1985, pp. 299–303. Nicholson, A.N., A.D. Handford, C. Turner, and B.M. Stone, “Studies on Performance and Sleepiness with the H1- antihistamine Desloratadine,” Aviation, Space, and Envi- ronmental Medicine, Vol. 74, No. 8, 2003, pp. 809–815. Nieman, D.C., et al., “Quercetin Ingestion Does Not Alter Cytokine Changes in Athletes Competing in the Western States Endurance Run,” Journal of Interferon Cytokine Research, Vol. 27, No. 12, 2007, pp. 1003–1011. Nieman, D.C., et al., “Effects of Quercetin and EGCG on Mito- chondrial Biogenesis and Immunity,” Medicine and Science Sports Exercise, Vol. 41, No. 7, 2009, pp. 1467–1475. Nishino, S. and E. Mignot, “Wake-promoting Medica- tions: Basic Mechanisms and Pharmacology,” Chapter 38, In: Principles and Practice of Sleep Medicine, 4th ed., M.H. Kryger, T. Roth, and W.C. Dement, Elsevier Saunders, Philadelphia, Pa., 2005, pp. 468–483. Nutto, E., “Psychomotor, Physiological and Cognitive Effects of Scopolamine and Ephedrine in Healthy Men,” European Journal of Clinical Pharmacology, Vol. 24, 1983, pp. 603–609. O’Brien, M.C., T.P. McCoy, S.D. Rhodes, A. Wagnoner, and M. Wolfson, “Caffeinated Cocktails: Energy Drink Consumption, High-risk Drinking, and Alcohol-related Consequences Among College Students,” Academic Emer- gency Medicine, Vol. 15, 2008, No. 5, pp. 453–460. Ogden, E.J. and H. Moskowitz, “Effects of Alcohol and Other Drugs on Driver Performance,” Traffic Injury Prevention, Vol. 5, No. 3, 2004, pp. 185–198. O’Hanlon, J.F., “Benzodiazepine Influence on Driving Proficiency: Workshop on Clinical Differentiation of Benzodiazepines,” Amsterdam, the Netherlands, June 14, 1985.

O’Hanlon, J.F. and J.J. DeGier, Drugs and Driving, Taylor and Francis, Ltd., London, U.K., 1986. O’Hanlon, J.F. and E.R. Volkerts, “Hypnotics and Actual Driving Performance,” Acta Psychiatry Scandinavia, Vol. 332, No. 74, Supplement, 1986, pp. 95–104. O’Hanlon, J.F. and H. Freeman, “Categorizing the Behavioral Toxicities of Antidepressants: Proposal and Requirements,” editorial, British Journal of Psychiatry, Vol. 166, 1995, pp. 421–423. O’Hanlon, J.F. and J.G. Ramaekers, “Antihistamine Effects on Actual Driving Performance in a Standard Test: A Summary of Dutch Experience, 1989–1994,” Allergy, Vol. 50, 1995, pp. 234–242. O’Hanlon, J.F., A. Vermeeren, M.M.C. Uiterwijk, L.M. Van Veggel, and H.F. Swijgman, “Anxiolytics’ Effects on Actual Driving Performance of Patients and Healthy Volunteers in a Standardized Test: An Integration of Three Studies,” Neuropsychobiology, Vol. 31, 1995, pp. 81–88. O’Hara, M., D. Kiefer, K. Farrell, and K. Kemper. “A Review of 12 Commonly Used Medicinal Herbs,” Archives of Fam- ily Medicine, Vol. 7, No. 6, 1998, pp. 523–536. Ojaniemi, K.K., T.P. Lintenon, A.O. Impinen, P.M. Lillsune, and A.I. Ostamo, “Trends in Driving Under the Influence of Drugs: A Register-based Study of DUID Suspects During 1977–2007,” Accident Analysis and Prevention, Vol. 41, 2008, pp. 191–196. Olson, P., “Driver Perception-Response Time,” Chapter 3, In: Human Factors in Traffic Safety, 2nd ed., R. Dewar and P. Olson, Eds., Lawyers and Judges Publishing Co., Inc., Tucson, Ariz., 2007, pp. 33–35. O’Neill, T.R., G.P. Krueger, and S.B. Van Hemel, Fatigue and the Truck Driver: Instructor’s Guide for a Fatigue Outreach Training Course for America’s Trucking Indus- try (A 4-hr course for safety and risk managers), Star Mountain, Inc. and the American Trucking Associations in partnership with the Federal Highway Administration, U.S. Department of Transportation, Alexandria, Va., 1996. Orris, P., S. Buchanan, A. Smiley, D. Davis, D. Dinges, and G. Bergoffen, CTBSSP Synthesis 9: Literature Review on Health and Fatigue Issues Associated with Commer- cial Motor Vehicle Driver Hours of Work, Transportation Research Board of the National Academies, Washington, D.C., 2005. Owasoyo, J.O., D.F. Neri, and J.G. Lamberth, “Tyrosine and Its Potential Use as a Countermeasure to Performance Decre- ment in Military Sustained Operations,” Aviation, Space, and Environmental Medicine, Vol. 63, 1992, pp. 364–369. Owen, T., “Ramelteon: Profile of a New Sleep-promoting Medication,” Drugs Today, Vol. 42, No. 4, 2006, p. 255. Pack, A.I., D. Dinges, and G. Maislin, A Study of Prevalence of Sleep Apnea Among Commercial Truck Drivers, FMCSA Technical Report No. RT-02-030, Office of Research and Technology, Federal Motor Carrier Safety Administration, U.S. Department of Transportation, Washington, D.C., May 2002. Pack, A.I., G. Maislin, S. Bethany, F.M. Pack, W.C. Rogers, C.F.P. George, and D.F. Dinges, “Impaired Performance in Commercial Drivers: Role of Sleep Apnea and Short Sleep 106 Duration,” American Journal of Respiratory and Critical Care Medicine, Vol. 174, 2006, No. 4, pp. 446–454. Parliament, T.H., C.-T. Ho, and P. Schieberle, Eds., Caffeinated Beverages: Health Benefits, Physiological Effects, and Chemistry, American Chemical Society (ACS) Symposium Series No. 754, Oxford University Press, Oxford, U.K., 2000. Parnell, S. and R. Callinan, “Soldiers’ Despair Confronts Defence” [Australian newspaper article about Royal Australian Air Force pilots becoming addicted to Stilnox as a sleep aid], July 10, 2010 [Online]. Available: www. theaustralian.com.au/news. Parrott, A.C. and G. Roberts, “Smoking Deprivation and Cigarette Reinstatement: Effects Upon Visual Attention,” Journal of Psychopharmacology, Vol. 5, 1991, 404–409. Pasternak, H.S., I. Jacobs, and D.G. Bell, “Effects of Ingesting Caffeine and Ephedrine on Muscular Endurance,” Cana- dian Journal of Applied Physiology, Vol. 24, 1999, p. S471. Paul, M.A., G. Gray, G. Kenny, and R. Pigeau, “Impact of Melatonin, Zaleplon, Zopiclone, and Temazepam on Psychomotor Performance,” Aviation, Space, and Envi- ronmental Medicine, Vol. 74, 2003, pp. 1263–1270. Paul, M.A., G. Gray, M. MacLellan, and R.A. Pigeau, “Sleep- inducing Pharmaceuticals: A Comparison of Melatonin, Zaleplon, Zopiclone, and Temazepam,” Aviation, Space, and Environmental Medicine, Vol. 75, 2004, pp. 512–519. Peloquin, L.J. and R. Klorman, “Effects of Methylphenidate on Normal Children’s Mood, Event-related Potentials and Performance in Memory Scanning and Vigilance,” Journal of Abnormal Psychology, Vol. 95, 1986, pp. 88–98. Penetar, D.M., G.L. Belenky, J.J. Garrigan, and D.P. Redmond, “Triazolam Impairs Learning and Fails to Improve Sleep in a Long-range Aerial Deployment,” Aviation, Space and Environmental Medicine, Vol. 60, 1989, pp. 594–598. Penetar, D., et al., “Caffeine Reversal of Sleep Deprivation Effects on Alertness and Mood,” Psychopharmacology, Vol. 112, 1993, pp. 359–365. Penetar, D., et al., “Effects of Caffeine on Cognitive Perfor- mance, Mood, and Alertness in Sleep Deprived Humans,” In: Food Components to Enhance Performance, Committee on Military Nutrition Research, Institute of Medicine, National Academy of Sciences, Washington, D.C., 1994, pp. 407–431. Perkins, K.A., L.H. Epstein, R.L. Stiller, J.E. Sexton, T.D. Debski, and R.G. Jacob, “Behavioral Performance Effects of Nicotine in Smokers and Nonsmokers,” Pharmacological and Biochemical Behavior, Vol. 37, 1990, pp. 11–15. Perkins, K.A., et al., “Chronic and Acute Tolerance to Sub- jective, Behavioral, and Cardiovascular Effects of Nicotine in Humans,” Journal of Pharmacological Experimental Therapy, Vol. 270, 1994, pp. 628–638. Petrie, K., J.V. Conaglen, L. Thompson, and K. Chamberlain, “Effects of Melatonin on Jet Lag After Long Haul Flights,” British Medical Journal, Vol. 298, 1989, pp. 705–707. Philip, P., et al., “The Effects of Coffee and Napping on Nighttime Highway Driving: A Randomized Trial,” Annals of Internal Medicine, Vol. 144, No. 11, 2006, pp. 785–791.

107 Pickworth, W.B., M.S. Rohrer, and R.V. Fant, “Effects of Abused Drugs on Psychomotor Performance,” Experimental Clinical Psychopharmacology, Vol. 5, 1997, pp. 235–241. Pigeau, R., et al., “Modafinil, d-Amphetamine and Placebo During 64 Hours of Sustained Mental Work: Effects on Mood, Fatigue, Cognitive Performance and Body Temperature,” Journal of Sleep Research, Vol. 4, 1995, pp. 212–228. Pittler, M.H., K. Schmidt, and E. Ernst, “Adverse Events of Herbal Food Supplements for Body Weight Reduction: Systematic Review,” Obesity Reviews, Vol. 6, No. 2, 2005, 93–111. Porter, J.M. and J.A. Horne, “Bed-time Food Supplements and Sleep: Effects of Different Carbohydrate Levels,” Electroencephalography and Clinical Neurophysiology, Vol. 51, 1981, pp. 426–433. Ramaekers, J.G., “Antidepressants and Driver Impairment: Empirical Evidence from a Standard on-the-Road Test,” Journal of Clinical Psychiatry, Vol. 64, 2003, pp. 20–29. Ramaekers, J.G. and J.F. O’Hanlon, “Acrivastine, Terfenadine and Diphenhydramine Effects on Driving Performance as a Function of Dose and Time After Dosing,” Euro- pean Journal of Clinical Pharmacology, Vol. 47, 1994, pp. 261–266. Ramaekers, J.G., M.M. Uiterwikk, and J.F. O’Hanlon, “Effects of Loratadine and Cetirizine on Actual Driving and Psychometric Test Performance and EEG During Driving,” European Journal of Clinical Pharmacology, Vol. 42, 1992, pp. 363–369. Ramaekers, J.G., L.M. van Veggel, and J.F. O’Hanlon, “A Cross-study Comparison of the Effects of Moclobemide and Brofaramine on Actual Driving Performance and Estimated Sleep,” Clinical Neuropharmacology, Vol. 17, Supplement 1, 1994, S9–S18. Ramaekers, J.G., N.D. Muntjeweerff, and J.F. O’Hanlon, “A Comparative Study of Acute and Subacute Effects of Dothiepin, Floxetine and Placebo on Psychomotor and Actual Driving Performance,” British Journal of Pharma- cology, Vol. 39, 1995, pp. 397–404. Ramaekers, J.G., G. Berghaus, M. Van Laar, and O.H. Drummer, “Dose-related Risk of Motor Vehicle Crashes After Cannabis Use,” Drug and Alcohol Dependence, Vol. 73, 2004, pp. 109–119. Reay, J.L., D.O. Kennedy, and A.B. Scholey, “Effects of Panax Ginseng, Consumed with and Without Glucose, on Blood Glucose Levels and Cognitive Performance During Sustained “Mentally Demanding” Tasks,” Jour- nal of Psychopharmacology, Vol. 20, No. 6, 2006, pp. 771–781. Reissig, C.J., E.C. Strain, and R.R. Griffiths, “Caffeinated Energy Drinks: A Growing Problem,” Drug and Alcohol Dependence, Vol. 99, No. 1–3, 2009, pp. 1–10. Reiter, R.J. and J. Robinson, Melatonin: Your Body’s Natural Wonder Drug, Bantam Books, New York, N.Y., 1995. Reisenhauber, A., M. Boehm, M. Posch, and C. Aufricht, “Diuretic Potential of Energy Drinks,” Amino Acids, Vol. 31, No. 1, 2006, pp. 81–83. Repantis, D., P. Schlattmann, O. Laisney, and L. Heuser, “Modafinil and Methylphenidate for Neuroenhancement in Healthy Individuals: A Systematic Review,” Pharmaco- logical Research, Vol. 62, No. 3, 2010, pp. 187–206. Reyner, L.A. and J.A. Horne, “Efficacy of a ‘Functional Energy Drink’ in Counteracting Driver Sleepiness,” Physiology and Behavior, Vol. 75, No. 3, 2002, pp. 331–335. Rice, V.J. and H.L. Snyder, “The Effects of Benadryl and Hismanal on Psychomotor Performance and Perceived Performance,” Aviation, Space and Environmental Medi- cine, Vol. 64, 1993, pp. 726–734. Richardson, G.S., T.A. Roehers, L. Rosenthal, G. Koshorek, and T. Roth, “Tolerance to Daytime Effects of Sedative H1 Antihistamines,” Journal of Clinical Psychopharma- cology, Vol. 22, 2002, pp. 511–515. Richardson, G.S., P.C. Zee, S. Wang-Weigand, L. Rodriguez, and X. Peng, “Circadian Phase-shifting Effects of Repeated Ramelteon Administration in Healthy Adults,” Journal of Clinical Sleep Medicine, Vol. 4, No. 5, 2008, pp. 456–461. Richalet, J.P., et al., “Sildenafil Inhibits Altitude-induced Hypoxemia and Pulmonary Hypertension,” American Jour- nal of Respiratory and Critical Care Medicine, Vol. 171, No. 3, 2005, pp. 275–281. Rigney, U., S. Kimber, and I. Hindmarch, “The Effects of Acute Doses of Standardized Ginkgo Biloba Extract on Memory and Psychomotor Performance in Volunteers,” Phytotherapy Research, Vol. 13, 1999, pp. 408–415. Robbe, H.W.J., Influence of Marijuana on Driving, University of Limburg, Maastricht, the Netherlands, 1994. Robbe, H.W.J. and J.F. O’Hanlan, Marijuana and Actual Driving Performance, DOT Highway Safety Technical Report 808078 (Nov. 1983), U.S. Department of Trans- portation, Washington, D.C., 1993. Robbe, H.W.J. and J.F. O’Hanlon, “Acute and Subchronic Effects of Paroxetine 20, and 40 mg on Actual Driving, Psychomotor Performance and Subjective Assessments in Healthy Volunteers,” European Neuropsychopharmacology, Vol. 5, 1995, pp. 35–42. Robbers, J.F. and V.E. Tyler, Tyler’s Herbs of Choice: The Therapeutic Use of Phytomedicinals, Haworth Press, Binghamton, N.Y., 2000, pp. 159–160. Roberts, S. and J. York, Design, Development and Evaluation of Truck and Bus Driver Wellness Programs: Final Report, FMCSA Technical Report, Office of Research and Tech- nology, Federal Motor Carrier Safety Administration, U.S. Department of Transportation, Washington, D.C., 2000 [Online]. Available: www.fmcsa.dot.gov. Robertson, P. and E.T. Hillriegel, “Clinical Pharmacokinetic Profile of Modafinil,” Clinical Pharmacokinetics, Vol. 42, 2003, pp. 123–137. Rodriguez, W.R. and R.A. Alfred, “Synthesis of trans- 4-Methylaminorex from Norephedrine and Potassium Cyanate,” DEA Technical Note, Southeast Laboratory, Drug Enforcement Administration, U.S. Department of Jus- tice, Miami, Fla., 2009 [Online]. Available: www.justice. gov.dea/programs/forensics. Roehers, T., D. Beare, F. Zorick, and T. Roth, “Sleepiness and Ethanol Effects on Simulated Driving,” Alcoholism:

Clinical Experimental Research, Vol. 18, No. 1, 1994, pp. 154–158. Rogers, P.J. and C. Dernoncourt, “Regular Caffeine Consump- tion: A Balance of Adverse and Beneficial Effects for Mood and Psychomotor Performance,” Pharmacology Bio- chemistry and Behavior, Vol. 59, 1998, pp. 1039–1045. Rogers, P.J., N.J. Richardson, and C. Dernoncourt, “Caffeine Use: Is There a Net Benefit for Mood and Psychomotor Performance?” Neuropsychobiology, Vol. 31, 1995, pp. 195–199. Ross, S. and D. Williams, “Buproprion: Risks and Benefits,” Expert Opinion on Drug Safety, Vol. 4, No. 6, 2005, pp. 995–1003. Roth, T., T. Roehers, G. Koshorek, J. Sicklesteel, and F. Zorick, “Sedative Effects of Antihistamines,” Journal of Allergy and Clinical Immunology, Vol. 80, 1987, pp. 94–98. Roth, T., T. Roehers, and G. Vogel, “Zolpidem in the Treatment of Transient Insomnia: A Double-blind, Randomized Comparison with Placebo,” Sleep, Vol. 18, 1995, 246–251. Rush, C.R., R.W. Baker, and K. Wright, “Acute Physiological and Behavioral Effects of Oral Cocaine in Humans: A Dose-response Analysis,” Drug and Alcohol Dependency, Vol. 55, 1999, pp. 1–12. Russo, M.B., “Recommendations for the Ethical Use of Pharmacologic Fatigue Countermeasures in the U.S. Military,” Aviation, Space, and Environmental Medicine, Vol. 78, No. 5, Section II, 2007, B119–B127. Sack, R.L., R.J. Hughes, M.L.N. Pires, and A.J. Lewy, “The Sleep-promoting Effects of Melatonin: Long-term Use of Hypnotic Medications,” Chapter 6, In: Insomnia Principles and Management, M.P. Szuba, J.D. Kloss, and D.F. Dinges, Cambridge University Press, Cambridge, U.K., 2003a. Sack, R.L., A.J. Lewy, M. Rittenbaum, and R.J. Hughes, “Chronobiology and Melatonin,” Chapter 4, In: Psycho- neuroendocrinology: The Scientific Basis of Clinical Prac- tice, O.M. Walkowitz and J.A. Rothschild, Eds., American Psychiatric Publishing, Inc., Arlington, Va., 2003b. Sagaspe, P., J. Taillard, G. Chaumet, N. Moore, B. Bioulac, and P. Philip, “Aging and Nocturnal Driving: Better with Coffee or a Nap?: A Randomized Study,” Sleep, Vol. 30, No. 12, 2007, pp. 1808–1813. Santhi, N., D. Aeschbach, T.S. Horowitz, and C.A. Czeisler, “The Impact of Sleep Timing and Bright Light Expo- sure on Attentional Impairment During Night Work.” Journal of Biological Rhythms, Vol. 23, No. 4, 2008, pp. 341–352. Satish, W., S. Streufert, M. Dewan, and S.V. Voort, “Improve- ments in Simulated Real-world Relevant Performance for Patients with Seasonal Allergic Rhinitis: Impact of Deslo- ratadine,” Allergy, Vol. 59, No. 4, 2004, pp. 415–420. Sato, Y., M. Terazawa, and K. Kainuma, “Guarana Extract- contained Drowsiness Preventive Gum,” Shokuhin Kogyo, Vol. 27, No. 12, 1984, pp. 73–81. Scharf, M.B. and D. Berkowitz, “Effects of Desloratadine and Alcohol Administration on Psychomotor Performance,” Current Medical Research Opinion, Vol. 23, No. 2, 2007, 313–321. 108 Scharf, M.B., T. Roth, G.W. Vogel, and J.K. Walsh, “A Multi- center, Placebo-controlled Study Evaluating Zolpidem in the Treatment of Chronic Insomnia,” Journal of Clinical Psychiatry, Vol. 55, 1994, pp. 192–199. Schnechtman, E. and D. Shinar, “Modeling Drug Detection and Diagnosis with the ‘Drug Evaluation and Classification Program,’” Accidents and Analysis Prevention, Vol. 37, No. 5, 2005, pp. 852–861. Scholey, A.B. and D.O. Kennedy, “Acute, Dose-dependent Cognitive Effects of Ginkgo Biloba, Panax Ginseng and Their Combination in Healthy Young Volunteers: Differential Interactions with Cognitive Demand,” Human Psychopharmacology, Vol. 17, No. 1, 2002, pp. 35–44. Schultz, D. and J.C. Miller, “Fatigue and Use of Go/No-go Pills in F-16 Pilots Subjected to Extraordinarily Long Combat Sorties,” AFRL Technical Report No. HE-BR- TR-2004-0014, Human Effectiveness Division, U.S. Air Force Research Laboratory, Brooks City Base, Tex., 2004a. Schultz, D. and J.C. Miller, “Fatigue and Use of Go/No-go Pills in Extraordinarily Long Combat Sorties [Commentary],” Aviation, Space, and Environmental Medicine, Vol. 75, 2004b, pp. 370–371. Schulz, H., C. Stolz, and J. Miller, “The Effect of Valerian Extract on Sleep Polygraphy in Poor Sleepers: A Pilot Study,” Pharmacopsychiatry, Vol. 27, 1994, pp. 147–151. Schweitzer, P.K., “Drugs That Disturb Sleep and Wakefulness,” Chapter 40, In: Principles and Practice of Sleep Medicine, 3rd ed., M.H. Kryger, T. Roth, and W.C. Dement, Eds., Elsevier Saunders, Philadelphia, Pa., 2005, pp. 499–518. Schweitzer, P.K., M.J. Muehlbach, and J.K. Walsh, “Sleepi- ness and Performance During Three-day Administration of Cetirizine or Diphenhydramine,” Journal of Allergy and Clinical Immunology, Vol. 94, 1994, pp. 716–724. Schweitzer, P.K., A.C. Randazzo, K. Stone, M. Erman, and J.K. Walsh, “Laboratory and Field Studies of Naps and Caffeine as Practical Countermeasures for Sleep-Wake Problems Associated with Night Work,” Sleep, Vol. 29, No. 1, 2006, pp. 39–50. Seidel, R., A. Perrl, R. Nicham, and E. Hauser, “A Taurine and Caffeine-containing Drink Stimulates Cognitive Performance and Well-being,” Amino Acids, Vol. 19, No. 3–4, 2000, pp. 635–642. Sherwood, N., “Effects of Nicotine on Human Psychomotor Performance,” Human Psychopharmacology: Clinical and Experimental, Vol. 8, 1993, pp. 155–184. Sherwood, N., “Effects of Cigarette Smoking on Performance in a Simulated Driving Task,” Neuropsychobiology, Vol. 32, No. 3, 1995, pp. 161–165. Shinar, D., “Drug Effects and Their Significance for Traffic Safety,” In: Transportation Research Circular No. E-C096: Drugs and Traffic: A Symposium, Transportation Research Board Committee on Alcohol and Other Drugs, Woods Hole, Mass., June 20–21, 2005, pp. 68–80. Shinar, D., “Alcohol and Driving,” Chapter 11, In: Traffic Safety and Human Behavior, D. Shinar, Ed., Elsevier, Amsterdam, the Netherlands, 2007a, pp. 403–462.

109 Shinar, D., “Drugs and Driving,” Chapter 12, In: Traffic Safety and Human Behavior, D. Shinar, Ed., Elsevier, Amsterdam, the Netherlands, 2007b, pp. 463–515. Shinar, D. and E. Schechtman, “Drug Identification Perfor- mance on the Basis of Observable Signs and Symptoms,” Accident Analysis and Prevention, Vol. 37, No. 5, 2005, pp. 843–851. Singer, C., K. Wild, R. Sack, and A. Lewy, “High Dose Melatonin Is Well Tolerated by the Elderly,” Sleep Research, Vol. 23, 1994, p. 86. Smiley, A., “Marijuana: On Road and Driving Simulator Studies,” In: The Health Effects of Cannabis, H. Kalant, W.A. Corrgall, W. Hall and R.G. Smart, Eds., Centre for Addiction and Mental Health, Toronto, ON, Canada, 1999. Smith, A. and G.H. Rubin, “Positive Effects of Caffeine or Negative Effects of Caffeine Withdrawal,” presentation Feb. 2–3, 1999, Institute of Medicine Workshop on Caffeine Formulations for Sustainment of Mental Task Performance during Military Operations, Committee on Military Nutrition Research, Washington, D.C. Smith, B.D. and K. Tola, “Caffeine: Effects on Psychological Functioning and Performance,” Chapter 12, In: Caffeine, G.A. Spiller, Ed., CRC Press, Boca Raton, Fla., 1998, pp. 251–299. Smith, S., Caffeine to Counteract Performance Deficits Due to Sleep Deprivation, presentation Feb. 2–3, 1999, Insti- tute of Medicine Workshop on Caffeine Formulations for Sustainment of Mental Task Performance during Military Operations, Committee on Military Nutrition Research, Washington, D.C., 1999. Solowij, N., Cannabis and Cognitive Functioning, Cambridge University Press, Cambridge, U.K., 1998. Soper, J.W., A.K. Chaturvedi, and D.V. Canfield, “Prevalence of Chlorpheniramine in Aviation Accident Pilot Fatalities, 1991–1996,” Aviation, Space and Environmental Medicine, Vol. 71, 2000, pp. 1206–1209. Soulimani, R., et al., “Behavioural Effects of Passiflora Incarnata L. and Its Indole Alkaloid and Flavonoid Deriva- tive and Maltol in the Mouse,” Journal of Ethnopharma- cology, Vol. 57, 1997, pp. 11–20. Spiller, G.A., Caffeine, CRC Press, Boca Raton, Fla., 1998. Spring, B., O. Maller, J. Wurtman, L. Digman, and L. Cozolino, “Effects of Protein and Carbohydrate Meals on Mood and Performance: Interactions with Sex and Age,” Journal of Psychiatric Research, Vol. 17, 1982, pp. 155–167. Stafford, R.S., “Regulating Off-label Drug Use: Rethinking the Role of the FDA,” New England Journal of Medicine, Vol. 358, No. 14, 2008, p. 1427. Steinke, L., J.S. Kalus, V. Dhanapal, D.E. Lanfear, and H.D. Berlie, “Energy Drink Consumption Causes Increases in Blood Pressure and Heart Rate,” Circulation, Vol. 116, 2007, p. II–831. Stone, B.M. and C. Turner, “Promoting Sleep in Shiftworkers and Intercontinental Travelers,” Chronobiology Inter- national, Vol. 14, 1997 pp. 133–143. Straus, S.E., “Herbal Medicines—What’s in the Bottle?” New England Journal of Medicine, Vol. 347, 2002, pp. 1997–1998. Struder, H.K., W. Hollmann, P. Platen, M. Donike, A. Gotz- mann, and K. Weber, “Influence of Paroxetine, Branched- chain Amino Acids and Tyrosine on Neuroendocrine System Responses and Fatigue in Humans,” Hormonal Metabolism Research, Vol. 30, No. 4, 1998, pp. 188–194. Su, T.P., M. Pagliaro, P.J. Schmidt, D. Pickar, O. Wolkoweitz, and D.R. Rubinow, “Neuropsychiatric Effects of Ana- bolic Steroids in Male Normal Volunteers,” Journal of the American Medical Association, Vol. 269, 1993, pp. 2760–2764. Taibi, D.M., C.A. Landis, H. Petry, and M.V. Vitiello, “A Systematic Review of Valerian as a Sleep Aid: Safe But Not Effective,” Sleep Medicine Review, Vol. 11, 2007, pp. 209–230. Talland, G.A., “Drug Enhancement of Human Memory and Attention: Experiments with Pemoline and Magnesium Hydroxide,” In: Drugs and Cerebral Function, W.L. Smith, Ed., Charles Thomas Publishers, Springfield, Ill., 1970, pp. 177–287. Technical Cooperation Program (TTCP), Assessment of Potential Physical and Cognitive Aids for Performance Enhancement of Conventional and Special Operations, 3rd ed., Report of Technical Panel 8, Technical Report TTCP HUM-01-11, The Technical Cooperation Program, Group HUM—Human Resources and Performance, Toronto, ON, Canada, 2001. [The panel member authors are listed above in the alphabetical file under the names Baranski et al. 2001]. Thomas, J.R., P.A. Lockwood, A. Singh, and P.A. Deuster, “Tyrosine Improves Working Memory in a Multitasking Environment,” Pharmacology and Biochemistry Behavior, Vol. 64, No. 3, 1999, pp. 495–500. Timmerman, H., “Why Are Non-sedating Antihistamines Non-sedating?” Clinical Experimental Allergy, Vol. 29, 1999, pp. 13–18. Transportation Research Board Committee on Alcohol, and Other Drugs, Transportation Research Circular No. E-C096: Drugs and Traffic: A Symposium, Woods Hole, Mass., June 20–21, 2005, Transportation Research Board of the National Academies, Washington, D.C., 2005, Tregear, S., et al., Psychiatric Disorders and Commercial Motor Vehicle Driver Safety, Executive Summary (Evidence Report), Federal Motor Carrier Safety Administration, U.S. Department of Transportation, Washington, D.C., Aug. 29, 2008 [Online]. Available: http://www.fmcsa.dot.gov/rules- regulations/TOPICS/mep/report/Psychiatric-Executive- Summary-prot.pdf [accessed Mar. 3, 2010]. Turino, G.M., et al., Conference on Pulmonary/Respiratory Disorders and Commercial Drivers, Technical Report: FHWA-MC-91-004, Office of Motor Carriers, Federal Highway Administration, U.S. Department of Transpor- tation, Washington, D.C., Mar. 1991 [Online]. Available: http://www.fmcsa.dot.gov/documents/pulmonary1.pdf [accessed Mar. 10, 2010].

Turner, C. and G.J. Spilich, “Research into Smoking or Nicotine and Human Cognitive Performance: Does the Source of Funding Make a Difference?” Addiction, Vol. 92, No. 11, 2006, pp. 1423–1426. Uchiumi, M., S. Isawa, M. Suzuki, and M. Murasaki, “The Effects of Zolpidem and Zopiclone on Daytime Sleepiness and Psychomotor Performance,” Nihon Shinkei Seishin Yakurigaku Zasshi, Vol. 20, No. 3, 2000, p. 12330. Underner, M., J. Paquereau, and J.C. Meurice, “Cigarette Smoking and Sleep Disturbance,” Revue des Maladies Respi- ratories, Vol. 23, No. 3, Supplement, 2006, pp. 6S67–6S77. U.S. Army Center for Health Promotion and Preventive Medicine (USA CHPPM), “The Warfighter’s Guide to Dietary Supplements: What You Really Need to Know,” CHPPM Technical Guide No. 295, U.S. Army Center for Health Promotion and Preventive Medicine, Edgewood Area of Aberdeen Proving Ground, Md., 2004. U.S. Department of Justice, Code of Federal Regulations (CFR), Title 21—Food and Drugs, Chapter 11, Part 1308, Schedules of Controlled Substances, and Chapter 13: Drug Abuse Prevention and Control, 2010, Drug Enforcement Administration, Washington, D.C. [Online]. Available: http://www.justice.gov/dea/pubs/csa.html. U.S. Department of Transportation, “Notice: Limitation on Alcohol Use by Transportation Workers,” Federal Register, Vol. 59, 1994, pp. 7302–7650. U.S. Navy, NATOPS General Flight and Operating Instruc- tions, OPNAV Instruction 3710.7S, U.S. Navy Head- quarters, Washington, D.C., 2001. U.S. Surgeon General’s Report on Smoking and Health, How Tobacco Causes Disease—The Biology— ... Nicotine Polacrilex Gum, etc., CDC Publication No. 88-846, U.S. Surgeon General, U.S. Department of Health and Human Services, Washington, D.C., 1988. Vacchiano, C., J. Moore, G.M. Rice, and G. Crawley, “Fexofenadine Effects on Cognitive Performance in Aviators at Ground Level and Simulated Altitude,” Aviation, Space, and Environmental Medicine, Vol. 79, 2008, pp. 754–760. Vallerand, A.L., J. Jacobs, and M.F. Kavanagh, “Mechanism of Enhanced Cold Tolerance by an Ephedrine-Caffeine Mixture in Humans,” Journal of Applied Physiology, Vol. 67, 1989, pp. 438–444. Van Camp, R.O., “Zolpidem in Fatigue Management for Surge Operations of Remotely Piloted Aircraft,” Aviation, Space and Environmental Medicine, Vol. 80, No. 6, 2009, pp. 553–555. Van Cauwenberge, P., et al., “Consensus Statement on the Treatment of Allergic Rhinitis: European Academy of Allergology and Clinical Immunology,” Allergy, Vol. 55, 2000, pp. 116–134. Van den Eynde, F., P.C. van Baelen, M. Portzky, and K. Audenaert, “The Effects of Energy Drinks on Cognitive Performance,” Tojdschr Psychiatry, Vol. 50, No. 5, 2008, pp. 273–281. Van Laar, M.W. and E.R. Volkerts, “Driving and Benzodi- azepine Use: Evidence That They Do Not Mix,” CNS Drugs, Vol. 10, 1998, pp. 383–396. 110 Van Laar, M.W., E.R. Volkerts, and A.P.P. Willigenburg, “Therapeutic Effects on Actual Driving Performance of Chronically Administered Buspirone and Diazepam in Anxious Outpatients,” Journal of Clinical Psychopharma- cology, Vol. 12, 1992, pp. 86–95. Vermeeren, A., “Residual Effects of Hypnotics: Epidemiology and Clinical Implications,” CNS Drugs, Vol. 18, No. 5, 2004, pp. 297–328. Voderholzer, U., et al., “Impact of Experimentally Induced Serotonin Deficiency by Tryptophan Depletion on Sleep EEG in Healthy Subjects,” Neuropsychopharmacology, Vol. 18, 1998, pp. 112–124. Volger, B.K., M.H. Pittler, and E. Ernst, “The Efficacy of Ginseng: A Systematic Review of Randomized Clinical Trials,” European Journal of Clinical Pharmacology, Vol. 55, 1999, pp. 567–575. Vuuman, E.F., G.H. Rikken, N.D. Muntjewerff, F. DeHalleux, and J.G. Ramaekers, “Effects of Desloratadine, Diphen- hydramine, and Placebo on Driving Performance and Psychomotor Performance Measurements,” European Journal of Clinical Pharmacology, Vol. 60, No. 5, 2004, pp. 307–313. Walker, T.H., et al., “Chemistry of Guaraná: Guaraná, Brazil’s Super-Fruit for the Caffeinated Beverages Industry,” Paper No. 31, In: Caffeinated Beverages: Health Benefits, Physiological Effects and Chemistry, T.H. Parliament, C.-T. Ho, and P. Schieberle, Eds., American Chemical Society Symposium Series No. 754, Oxford University Press, Oxford, U.K., 2000. Walsh, J.K., A.C. Randazzo, K.L. Stone, and P.K. Schweitzer, “Modafinial Improves Alertness, Vigilance, and Executive Function During Simulated Night Shifts,” Sleep, Vol. 27, No. 3, 2004, pp. 434–439. Warburton, D.M., “Effects of Caffeine on Cognition and Mood Without Caffeine Abstinence,” Psychopharmacology, Vol. 119, 1995, pp. 66–70. Warburton, D.M., E. Bersellini, and E. Sweeney, “An Eval- uation of a Caffeinated Taurine Drink on Mood, Memory and Information Processing in Healthy Volunteers Without Caffeine Abstinence,” Psychopharmacology, Vol. 158, No. 3, 2001, pp. 322–328. Warot, D., et al., “Comparative Effects of Ginkgo Biloba Extracts on Psychomotor Performance and Memory in Healthy Subjects,” Therapie, Vol. 46, No. 1, 1991, pp. 33–36. Waterhouse, J., T. Reilly, and G. Atkinson, “Jet-lag,” Lancet, Vol. 350, 1997, pp. 1611–1616. Weiler, J.M., et al., “Effects of Fexofenadine, Diphen- hydramine, and Alcohol on Driving Performance: A Randomized, Placebo-controlled Trial in the Iowa Driving Simulator,” Annals of Internal Medicine, Vol. 132, No. 5, 2000, pp. 354–363. Wells, A.S., N.W. Read, K. Uvnas-Moberg, and P. Alster, “Influences of Fat and Carbohydrate on Postprandial Sleepiness, Mood, and Hormones,” Physiology and Behavior, Vol. 61, 1997, pp. 679–686.

111 Wesensten, N.J., T.J. Balkin, and G.L. Belenky, “Effects of Daytime Administration of Zolpidem and Triazolam on Performance,” Aviation, Space and Environmental Medicine, Vol. 67, No. 2, 1996, pp. 115–120. Wesensten, N.J., G. Belenky, M.A. Kautz, D. Thorne, R.M. Reichardt, and T. Balkin, “Maintaining Alertness and Per- formance During Sleep Deprivation: Modafinil Versus Caf- feine,” Psychopharmacology, Vol. 159, 2002, pp. 238–247. Wesensten, N.J., G. Belenky, D.R. Thorne, M.A. Kautz, and T.J. Balkin, “Modafinil vs. Caffeine: Effects on Fatigue During Sleep Deprivation, Aviation, Space, and Environ- mental Medicine, Vol. 75, No. 6, 2004a, 520–525. Wesensten, N., et al., “Caffeine, Dextroamphetamine, and Modafinil During 85 Hours of Sleep Deprivation. I. Per- formance and Alertness Effects,” Aviation, Space, and Environmental Medicine, Vol. 75 (4 Supplement), 2004b, p. B108. Wesensten, N.J., T.J. Balkin, R.M. Reichardt, M.A. Kautz, G.A. Saviolakis, and G.L. Belenky, “Daytime Sleep and Performance Following a Zolpidem and Melatonin Cock- tail,” Sleep, Vol. 28, No. 1, 2005a, pp. 93–103. Wesensten, N.J., W.D.S. Killgore, and T.J. Balkin, “Perfor- mance and Alertness Effects of Caffeine, Dextroampheta- mine, and Modafinil During Sleep Deprivation,” Journal of Sleep Research, Vol. 14, 2005b, pp. 255–266. Wesnes, K.A., et al., “The Cognitive, Subjective, and Physical Effects of a Ginkgo Biloba/Panax Ginseng Combination in Healthy Volunteers with Neurasthenic Complaints,” Psychopharmacological Bulletin, Vol. 33, No. 4, 1997, pp. 677–683. Whitmore, J.N., J.R. Fischer, and W.F. Storm, “Hypnotic Effi- cacy of Zaleplon for Daytime Sleep in Rested Individuals,” Sleep, Vol. 27, No. 5, 2004, pp. 895–898. Whitmore, J., et al., A Double-blind Placebo-controlled Investigation of the Efficacy of Modafinil for Maintaining Alertness and Performance in Sustained Military Opera- tions, AFRL-HE-BR-Technical Report No. TR-2006-0005, Human Effectiveness Directorate, Air Force Research Laboratory, Brooks City Base, Tex., 2006. Willette, R.E. and J.M. Walsh, Drugs, Driving, and Traffic Safety, World Health Organization Publication No. 78, The World Health Organization, Geneva, Switzerland, 1983. Williams, C., “Dietary Macro- and Micronutrient Requirements of Endurance Athletes,” Proceedings of the Nutrition Society, Vol. 57, 1998, pp. 1–8. Williams, M.H., “Vitamin Supplementation and Athletic Performance,” International Journal of Vitamin and Nutri- tional Research, Supplement, Vol. 30, 1989, p. 163. Williamson, D.J. and A.H. Young, “Psychiatric Effects of Androgenic and Anabolic-adrogenic Steroid Abuse in Men: A Review of the Literature,” Journal of Psycho- pharmacology, Vol. 6, 1992, pp. 20–26. Willoughby, S., “Red Bull Lifts Stroke Risk: Australian Study,” Canberra Australia Reuters News, interview, Sep. 5, 2008. Wilson, W.M. and R.J. Maughan, “Evidence for a Possible Role of 5-hydroxytryptamine in the Genesis of Fatigue in Man: Administration of Paroxethin,” a 5-HT Re-uptake Inhibitor, Reduces the Capacity to Perform Prolonged Exercise, Experimental Physiology, Vol. 77, 1992, pp. 921–924. Wilson, W.H., E.H. Elllinwood, R.J. Matthew, and K. Johnson, “Effects of Marijuana on Performance of a Computerized Cognitive-neuromotor Test Battery,” Psychiatry Research, Vol. 51, 1994, pp. 115–125. Wittenborn, J.R., “Effects of Benzodiazepines on Psycho- motor Performance,” British Journal of Clinical Pharma- cology, Vol. 7 (Supplement 1), 1979, pp. 61S–67S. Wolf, O.T. and C. Kirschbaum, “Endogenous Estradiol and Testosterone Levels Are Associated with Cognitive Perfor- mance in Older Women and Men,” Hormonal Behavior, Vol. 41, 2002, pp. 259–266. Wolf, O.T., et al., “Associations Between Circulating Sex Steroid Hormones and Cognition in Normal Elderly Women,” Journal of Clinical Endocrinology and Metabo- lism, Vol. 82, 1997, pp. 2363–2367. Wolfe, R., “Protein Supplements and Exercise,” American Journal of Clinical Nutrition, Vol. 72, 2000, pp. 551S–557S. Woojae, K., “Debunking the Effects of Taurine in Red Bull Energy Drink,” Nutrition Bytes, Vol. 9, 2003, pp. 1–9. Wurtman, R.J., F. Hefti, and E. Melamed, “Precursor Control of Neurotransmitter Synthesis,” Pharmacology Review, Vol. 32, No. 4, 1980, pp. 315–335. Young, R., M. Gabryszuk, and R.A. Glennon, “Ephedrine and Caffeine Mutually Potentiate One Another’s Amphetamine- like Stimulus Effects,” Pharmacology, Biochemistry, and Behavior, Vol. 61, 1988, pp. 169–173. Zammit, G., M. Erman, S. Wang-Weigand, S. Sainati, J. Zhang, and T. Roth, “Evaluation of the Efficacy and Safety of Rameleon in Subjects with Chronic Insomnia,” Journal of Clinical Sleep Medicine, Vol. 3, No. 5, 2007, pp. 495–504. Zhdanova, I.V., R.J. Wurtman, and D.L. Schomer, “Sleep- inducing Effects of Low Doses of Melatonin Ingested in the Evening,” Clinical Pharmacology and Therapeutics, Vol. 57, 1995, pp. 552–558. Ziemba, A.W., J. Chmura, H. Kaciuba-Uscilko, K. Nazar, P. Wisnik, and R. Gawronski, “Ginseng Treatment Improves Psychomotor Performance at Rest and During Graded Exercise in Young Athletes,” International Journal of Sports Nutrition, Vol. 9, 1999, 371–377.